A Phase 1 interventional study of PF-06882961 and Atorvastatin in Healthy Adults, sponsored by Pfizer. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-08-19.
Sponsored by Pfizer · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to characterize the effect of PF-06882961, administered at 2 steady-state dose levels, on the PK of single doses of atorvastatin (20 mg) or midazolam (5 mg), administered separately, in healthy adult male and female participants (Part A), or an OC in healthy PM female participants (Part B).
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants with ANY of the following abnormalities in clinical laboratory tests at Screening, as assessed by the study specific laboratory and confirmed by a single repeat test, if deemed necessary:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
To evaluate the effect of 2 steady-state dose levels of PF-06882961 on the Single Dose pharmacokinetics of atorvastatin (20 mg tablet) and midazolam (5 mg syrup).
Drug: PF-06882961 · Drug: Atorvastatin · Drug: Midazolam
To evaluate the effect of 2 steady-state dose levels of PF-06882961 on the Single Dose pharmacokinetics of an Oral Contraceptive (Levonorgestrel 0.15 mg and Ethinyl Estradiol 0.03 mg tablet).
Drug: PF-06882961 · Drug: Levonorgestrel & Ethinyl Estradiol
Tablets
Tablets
Syrup
Drug pages: Levonorgestrel · Ethinyl Estradiol
Tablet
(Part A) Area Under the Concentration-time Curve From Time 0 to Infinity (AUCinf) of Atorvastatin in Periods 1, 4, and 7
Atorvastatin was given on Day 1 in Periods 1, 4 and 7 of Part A and blood samples were collected for atorvastatin pharmacokinetic (PK) at the preset time points described in the Time Frame. AUCinf calculated area under the plasma concentration-time profile from time 0 extrapolated to infinite time.
Time frame: For Part A Periods 1, 4, and 7: At 0 (prior to atorvastatin dose), 0.5, 1, 1.5, 2, 4, 6, 9, 12, 24, 36, 48, 72 hours (only Periods 1 & 4) post atorvastatin dose on Day 1 of each period.
(Part A) AUCinf of Midazolam in Periods 2, 5, and 8
Midazolam was given on Day 1 in Periods 2, 5 and 8 of Part A and blood samples were collected for midazolam PK at the preset time points described in the Time Frame. AUCinf calculated area under the plasma concentration-time profile from time 0 extrapolated to infinite time.
Time frame: For Part A Periods 2, 5, and 8: At 0 (prior to midazolam dose), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24 hours (only for Periods 2 & 5) post midazolam dose on Day 1 of each period.
(Part B) AUCinf of Levonorgestrel in Periods 1, 3 and 5
Levonorgestrel was given on Day 1 in Periods 1, 3 and 5 of Part B and blood samples were collected for levonorgestrel PK at the preset time points described in the Time Frame. AUCinf calculated area under the plasma concentration-time profile from time 0 extrapolated to infinite time.
Time frame: For Part B Periods 1, 3, 5: At 0 (prior to levonorgestrel dose), 0.5, 1, 1.5, 2, 4, 8, 12, 24, 48, 72, 96, 120 hours post levonorgestrel dose on Day 1 of each period.
(Part B) AUCinf of Ethinyl Estradiol in Periods 1, 3 and 5
Ethinyl estradiol (EE) was given on Day 1 in Periods 1, 3 and 5 of Part B and blood samples were collected for ethinyl estradiol PK at the preset time points described in the Time Frame. AUCinf calculated area under the plasma concentration-time profile from time 0 extrapolated to infinite time.
Time frame: For Part B Periods 1, 3, 5: At 0 (prior to EE dose), 0.5, 1, 1.5, 2, 4, 8, 12, 24, 48, 72, 96, 120 hours post EE dose on Day 1 in Periods 1, 3, 5 of each period.
(Part A) Number of Participants With Treatment Emergent Adverse Events (TEAE) During Part A of the Study
An AE was any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An serious adverse event was defined as any untoward medical occurrence that,at any dose:resulted in death;was life-threatening;required inpatient hospitalization or prolongation of existing hospitalization;resulted in persistent disability/incapacity; was a congenital anomaly/birth defect;or other serious situations such as important medical events. The investigator was required to use clinical judgment to assess the potential relationship between investigational product and each AE, to define an treatment-related AE.
Time frame: From Baseline up to follow-up telephone contact (Days 90-97) in Part A of the study.
(Part B) Number of Participants With TEAE During Part B of the Study
An AE was any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An serious adverse event was defined as any untoward medical occurrence that,at any dose:resulted in death;was life-threatening;required inpatient hospitalization or prolongation of existing hospitalization;resulted in persistent disability/incapacity; was a congenital anomaly/birth defect;or other serious situations such as important medical events. The investigator was required to use clinical judgment to assess the potential relationship between investigational product and each AE, to define an treatment-related AE.
Time frame: From Baseline up to follow-up telephone contact (Days 94-101) in Part B of the study.
(Part A) Number of Participants With Clinical Laboratory Abnormalities During Part A of the Study (Without Regard to Baseline Abnormality)
Laboratory tests (including hematology, clinical chemistry, urinalysis) were reported and abnormalities were defined for laboratory values that met specific criteria.
Time frame: From Baseline up to follow-up visit (Days 69-72) in Part A of the study.
(Part B) Number of Participants With Clinical Laboratory Abnormalities During Part B of the Study (Without Regard to Baseline Abnormality)
Laboratory tests (including hematology, clinical chemistry, urinalysis) were reported and abnormalities were defined for laboratory values that met specific criteria.
Time frame: From Baseline up to follow-up visit (Days 72-75) in Part B of the study.
(Part A) Number of Participants With Vital Signs Abnormalities During Part A of the Study
Supine blood pressure (mm Hg) and pulse rate (beats per minute) were measured. Supine BP was measured with the participant's arm supported at heart level and recorded to the nearest mmHg after approximately 5 minutes of rest.
Time frame: From Baseline up to follow-up visit (Days 69-72) in Part A of the study.
(Part B) Number of Participants With Vital Signs Abnormalities During Part B of the Study
Supine blood pressure (mm Hg) and pulse rate (bpm) were measured. Supine BP was measured with the participant's arm supported at heart level and recorded to the nearest mmHg after approximately 5 minutes of rest.
Time frame: From Baseline up to follow-up visit (Days 72-75) in Part B of the study.
(Part A) Percentage of Change From Baseline in Body Weight
Percentage of changes from Baseline in body weight of the participants were measured.
Time frame: Percentage of change from Baseline 1: from the last pre-dose measurement in Part A Period 1 (ie, Baseline 1) to Day 2 of Part A Period 8; percentage of Change from the last predose measurement in Part A Period 3 (ie, Baseline 2) to Day 2 of Period 8.
(Part B) Percentage of Change From Baseline in Body Weight
Percentage of changes from Baseline in body weight of the participants were measured.
Time frame: Percentage of Change from Baseline 1:from the last pre-dose measurement in Part B Period 1 (ie, Baseline 1) to Day 2 of Part B Period 8;percentage of Change from the last predose measurement in Part B Period 2 (ie, Baseline 2) to Day 6 of Part B Period 5.
(Part A) Number of Participants With Treatment Emergent Electrocardiograms (ECG) Abnormalities During Part A of the Study
Standard 12-lead ECGs utilizing limb leads were collected using an ECG machine that automatically calculated the heart rate and measured PR, QT, and QT interval corrected for heart rate (QTc) and QRS complex.
Time frame: From Baseline up to follow-up visit (Days 69-72) in Part A of the study.
(Part B) Number of Participants With Treatment Emergent ECG Abnormalities During Part B of the Study
Standard 12-lead ECGs utilizing limb leads were collected using an ECG machine that automatically calculated the heart rate and measured PR, QT, and QT interval corrected for heart rate (QTc) and QRS complex.
Time frame: From Baseline up to follow-up visit (Days 72-75) in Part B of the study.
(Part A) Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS)
The C-SSRS was an interview-based rating scale to systematically assess suicidal ideation and suicidal behavior. C-SSRS assessed whether participant experienced any of the following 1: completed suicide, 2: suicide attempt (response of "yes" on "actual attempt"), 3: preparatory acts toward imminent suicidal behavior ("yes" on "aborted attempt", "interrupted attempt", "preparatory acts or behavior"), 4: any suicidal behavior or ideation, suicidal ideation ("yes" on "wish to be dead", "non-specific active suicidal thoughts"), 7: self-injurious behavior, no suicidal intent ("yes" on "has participant engaged in non-suicidal self-injurious behavior").
Time frame: Study Day -1 (D-1) (ie, Period 1 Day-1 [P1D-1]), D5 (P3D1), D12 (P3D8), D19 (P3D15), D27 (P3D23), D36 (P4D1), D40 (P6D1), D48 (P6D9), D58 (P6D19), D62 (P8D1), and at follow-up visit (Days 69-72) of Part A.
(Part B) Number of Participants With Categorical Scores on the C-SSRS
The C-SSRS was an interview-based rating scale to systematically assess suicidal ideation and suicidal behavior. C-SSRS assessed whether participant experienced any of the following 1: completed suicide, 2: suicide attempt (response of "yes" on "actual attempt"), 3: preparatory acts toward imminent suicidal behavior ("yes" on "aborted attempt", "interrupted attempt", "preparatory acts or behavior"), 4: any suicidal behavior or ideation, suicidal ideation ("yes" on "wish to be dead", "non-specific active suicidal thoughts"), 7: self-injurious behavior, no suicidal intent ("yes" on "has participant engaged in non-suicidal self-injurious behavior").
Time frame: Study Day -1 (D-1) (ie, Period 1 Day-1 [P1D-1]), D6 (P2D1), D13 (P2D8), D20 (P2D15), D27 (P2D22), D37 (P3D1), D42 (P4D1), D50 (P4D9), D60 (P4D19), D66 (P5D6), and at follow-up visit (Days 72-75) of Part B.
(Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9)
The PHQ-9 is a 9 item self-report scale for the assessment of depressive symptoms. The questions included "little interest/pleasure in things", "feeling down depressed or hopeless", "trouble falling or staying asleep", "feeling tired or little energy", "poor appetite or overeating", "feeling bad about yourself", "trouble concentrating on things", "moving slowly or fidgety/restless" and "thoughts you be better off dead". Each item was scored on scale of "not at all", "several days", "more than half the days" to "nearly every day". Total score range: 0-27 (each item with scale from 0 \[not at all\] to 3 \[nearly every day\]. Higher score=greater severity).
Time frame: Study Day -1 (D-1) (ie, Period 1 Day-1 [P1D-1]), D5 (P3D1), D12 (P3D8), D19 (P3D15), D27 (P3D23), D36 (P4D1), D40 (P6D1), D48 (P6D9), D58 (P6D19), D62 (P8D1), and at follow-up visit (Days 69-72) of Part A.
(Part B) Number of Participants With Categorical Scores on the PHQ-9
The PHQ-9 is a 9 item self-report scale for the assessment of depressive symptoms. The questions included "little interest/pleasure in things", "feeling down depressed or hopeless", "trouble falling or staying asleep", "feeling tired or little energy", "poor appetite or overeating", "feeling bad about yourself", "trouble concentrating on things", "moving slowly or fidgety/restless" and "thoughts you be better off dead". Each item was scored on scale of "not at all", "several days", "more than half the days" to "nearly every day". Total score range: 0-27 (each item with scale from 0 \[not at all\] to 3 \[nearly every day\]. Higher score=greater severity).
Time frame: Study Day -1 (D-1) (ie, Period 1 Day-1 [P1D-1]), D6 (P2D1), D13 (P2D8), D20 (P2D15), D27 (P2D22), D37 (P3D1), D42 (P4D1), D50 (P4D9), D60 (P4D19), D66 (P5D6), and at follow-up visit (Days 72-75) of Part B.
| Milestone | Atorvastatin 20 mg (Part A Period 1) | Midazolam 5 mg (Part A Period 2) | PF-06882961 Titration up to 120 mg BID (Part A Period 3) | PF-06882961 120 mg BID + Atorvastatin 20 mg (Part A Period 4) | PF-06882961 120 mg BID + Midazolam 5 mg (Part A Period 5) | PF-06882961 Titration up to 200 mg BID (Part A Period 6) | PF-06882961 200 mg BID + Atorvastatin 20 mg (Part A Period 7) | PF-06882961 200 mg BID + Midazolam 5 mg (Part A Period 8) | 0.15 mg LE & 0.03 mg EE (Part B Period 1) | PF-06882961 Titration up to 120 mg BID (Part B Period 2) | PF-06882961 120 mg BID + 0.15 mg LE & 0.03 mg EE (Part B Period 3) | PF-06882961 Titration up to 200 mg BID (Part B Period 4) | PF-06882961 200 mg BID + 0.15 mg LE & 0.03 mg EE (Part B Period 5) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 18 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 18 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Atorvastatin 20 mg (Part A Period 1) | Midazolam 5 mg (Part A Period 2) | PF-06882961 Titration up to 120 mg BID (Part A Period 3) | PF-06882961 120 mg BID + Atorvastatin 20 mg (Part A Period 4) | PF-06882961 120 mg BID + Midazolam 5 mg (Part A Period 5) | PF-06882961 Titration up to 200 mg BID (Part A Period 6) | PF-06882961 200 mg BID + Atorvastatin 20 mg (Part A Period 7) | PF-06882961 200 mg BID + Midazolam 5 mg (Part A Period 8) | 0.15 mg LE & 0.03 mg EE (Part B Period 1) | PF-06882961 Titration up to 120 mg BID (Part B Period 2) | PF-06882961 120 mg BID + 0.15 mg LE & 0.03 mg EE (Part B Period 3) | PF-06882961 Titration up to 200 mg BID (Part B Period 4) | PF-06882961 200 mg BID + 0.15 mg LE & 0.03 mg EE (Part B Period 5) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 15 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 15 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Atorvastatin 20 mg (Part A Period 1) | Midazolam 5 mg (Part A Period 2) | PF-06882961 Titration up to 120 mg BID (Part A Period 3) | PF-06882961 120 mg BID + Atorvastatin 20 mg (Part A Period 4) | PF-06882961 120 mg BID + Midazolam 5 mg (Part A Period 5) | PF-06882961 Titration up to 200 mg BID (Part A Period 6) | PF-06882961 200 mg BID + Atorvastatin 20 mg (Part A Period 7) | PF-06882961 200 mg BID + Midazolam 5 mg (Part A Period 8) | 0.15 mg LE & 0.03 mg EE (Part B Period 1) | PF-06882961 Titration up to 120 mg BID (Part B Period 2) | PF-06882961 120 mg BID + 0.15 mg LE & 0.03 mg EE (Part B Period 3) | PF-06882961 Titration up to 200 mg BID (Part B Period 4) | PF-06882961 200 mg BID + 0.15 mg LE & 0.03 mg EE (Part B Period 5) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 18 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 0 | 17 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Physician decision | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Atorvastatin 20 mg (Part A Period 1) | Midazolam 5 mg (Part A Period 2) | PF-06882961 Titration up to 120 mg BID (Part A Period 3) | PF-06882961 120 mg BID + Atorvastatin 20 mg (Part A Period 4) | PF-06882961 120 mg BID + Midazolam 5 mg (Part A Period 5) | PF-06882961 Titration up to 200 mg BID (Part A Period 6) | PF-06882961 200 mg BID + Atorvastatin 20 mg (Part A Period 7) | PF-06882961 200 mg BID + Midazolam 5 mg (Part A Period 8) | 0.15 mg LE & 0.03 mg EE (Part B Period 1) | PF-06882961 Titration up to 120 mg BID (Part B Period 2) | PF-06882961 120 mg BID + 0.15 mg LE & 0.03 mg EE (Part B Period 3) | PF-06882961 Titration up to 200 mg BID (Part B Period 4) | PF-06882961 200 mg BID + 0.15 mg LE & 0.03 mg EE (Part B Period 5) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 15 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 0 | 15 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Atorvastatin 20 mg (Part A Period 1) | Midazolam 5 mg (Part A Period 2) | PF-06882961 Titration up to 120 mg BID (Part A Period 3) | PF-06882961 120 mg BID + Atorvastatin 20 mg (Part A Period 4) | PF-06882961 120 mg BID + Midazolam 5 mg (Part A Period 5) | PF-06882961 Titration up to 200 mg BID (Part A Period 6) | PF-06882961 200 mg BID + Atorvastatin 20 mg (Part A Period 7) | PF-06882961 200 mg BID + Midazolam 5 mg (Part A Period 8) | 0.15 mg LE & 0.03 mg EE (Part B Period 1) | PF-06882961 Titration up to 120 mg BID (Part B Period 2) | PF-06882961 120 mg BID + 0.15 mg LE & 0.03 mg EE (Part B Period 3) | PF-06882961 Titration up to 200 mg BID (Part B Period 4) | PF-06882961 200 mg BID + 0.15 mg LE & 0.03 mg EE (Part B Period 5) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 17 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 0 | 0 | 13 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Physician decision | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Atorvastatin 20 mg (Part A Period 1) | Midazolam 5 mg (Part A Period 2) | PF-06882961 Titration up to 120 mg BID (Part A Period 3) | PF-06882961 120 mg BID + Atorvastatin 20 mg (Part A Period 4) | PF-06882961 120 mg BID + Midazolam 5 mg (Part A Period 5) | PF-06882961 Titration up to 200 mg BID (Part A Period 6) | PF-06882961 200 mg BID + Atorvastatin 20 mg (Part A Period 7) | PF-06882961 200 mg BID + Midazolam 5 mg (Part A Period 8) | 0.15 mg LE & 0.03 mg EE (Part B Period 1) | PF-06882961 Titration up to 120 mg BID (Part B Period 2) | PF-06882961 120 mg BID + 0.15 mg LE & 0.03 mg EE (Part B Period 3) | PF-06882961 Titration up to 200 mg BID (Part B Period 4) | PF-06882961 200 mg BID + 0.15 mg LE & 0.03 mg EE (Part B Period 5) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 15 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 0 | 0 | 15 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Atorvastatin 20 mg (Part A Period 1) | Midazolam 5 mg (Part A Period 2) | PF-06882961 Titration up to 120 mg BID (Part A Period 3) | PF-06882961 120 mg BID + Atorvastatin 20 mg (Part A Period 4) | PF-06882961 120 mg BID + Midazolam 5 mg (Part A Period 5) | PF-06882961 Titration up to 200 mg BID (Part A Period 6) | PF-06882961 200 mg BID + Atorvastatin 20 mg (Part A Period 7) | PF-06882961 200 mg BID + Midazolam 5 mg (Part A Period 8) | 0.15 mg LE & 0.03 mg EE (Part B Period 1) | PF-06882961 Titration up to 120 mg BID (Part B Period 2) | PF-06882961 120 mg BID + 0.15 mg LE & 0.03 mg EE (Part B Period 3) | PF-06882961 Titration up to 200 mg BID (Part B Period 4) | PF-06882961 200 mg BID + 0.15 mg LE & 0.03 mg EE (Part B Period 5) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 13 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 13 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Atorvastatin 20 mg (Part A Period 1) | Midazolam 5 mg (Part A Period 2) | PF-06882961 Titration up to 120 mg BID (Part A Period 3) | PF-06882961 120 mg BID + Atorvastatin 20 mg (Part A Period 4) | PF-06882961 120 mg BID + Midazolam 5 mg (Part A Period 5) | PF-06882961 Titration up to 200 mg BID (Part A Period 6) | PF-06882961 200 mg BID + Atorvastatin 20 mg (Part A Period 7) | PF-06882961 200 mg BID + Midazolam 5 mg (Part A Period 8) | 0.15 mg LE & 0.03 mg EE (Part B Period 1) | PF-06882961 Titration up to 120 mg BID (Part B Period 2) | PF-06882961 120 mg BID + 0.15 mg LE & 0.03 mg EE (Part B Period 3) | PF-06882961 Titration up to 200 mg BID (Part B Period 4) | PF-06882961 200 mg BID + 0.15 mg LE & 0.03 mg EE (Part B Period 5) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 13 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 13 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Atorvastatin 20 mg (Part A Period 1) | Midazolam 5 mg (Part A Period 2) | PF-06882961 Titration up to 120 mg BID (Part A Period 3) | PF-06882961 120 mg BID + Atorvastatin 20 mg (Part A Period 4) | PF-06882961 120 mg BID + Midazolam 5 mg (Part A Period 5) | PF-06882961 Titration up to 200 mg BID (Part A Period 6) | PF-06882961 200 mg BID + Atorvastatin 20 mg (Part A Period 7) | PF-06882961 200 mg BID + Midazolam 5 mg (Part A Period 8) | 0.15 mg LE & 0.03 mg EE (Part B Period 1) | PF-06882961 Titration up to 120 mg BID (Part B Period 2) | PF-06882961 120 mg BID + 0.15 mg LE & 0.03 mg EE (Part B Period 3) | PF-06882961 Titration up to 200 mg BID (Part B Period 4) | PF-06882961 200 mg BID + 0.15 mg LE & 0.03 mg EE (Part B Period 5) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 13 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 | 13 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Atorvastatin 20 mg (Part A Period 1) | Midazolam 5 mg (Part A Period 2) | PF-06882961 Titration up to 120 mg BID (Part A Period 3) | PF-06882961 120 mg BID + Atorvastatin 20 mg (Part A Period 4) | PF-06882961 120 mg BID + Midazolam 5 mg (Part A Period 5) | PF-06882961 Titration up to 200 mg BID (Part A Period 6) | PF-06882961 200 mg BID + Atorvastatin 20 mg (Part A Period 7) | PF-06882961 200 mg BID + Midazolam 5 mg (Part A Period 8) | 0.15 mg LE & 0.03 mg EE (Part B Period 1) | PF-06882961 Titration up to 120 mg BID (Part B Period 2) | PF-06882961 120 mg BID + 0.15 mg LE & 0.03 mg EE (Part B Period 3) | PF-06882961 Titration up to 200 mg BID (Part B Period 4) | PF-06882961 200 mg BID + 0.15 mg LE & 0.03 mg EE (Part B Period 5) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 13 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 | 13 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Atorvastatin 20 mg (Part A Period 1) | Midazolam 5 mg (Part A Period 2) | PF-06882961 Titration up to 120 mg BID (Part A Period 3) | PF-06882961 120 mg BID + Atorvastatin 20 mg (Part A Period 4) | PF-06882961 120 mg BID + Midazolam 5 mg (Part A Period 5) | PF-06882961 Titration up to 200 mg BID (Part A Period 6) | PF-06882961 200 mg BID + Atorvastatin 20 mg (Part A Period 7) | PF-06882961 200 mg BID + Midazolam 5 mg (Part A Period 8) | 0.15 mg LE & 0.03 mg EE (Part B Period 1) | PF-06882961 Titration up to 120 mg BID (Part B Period 2) | PF-06882961 120 mg BID + 0.15 mg LE & 0.03 mg EE (Part B Period 3) | PF-06882961 Titration up to 200 mg BID (Part B Period 4) | PF-06882961 200 mg BID + 0.15 mg LE & 0.03 mg EE (Part B Period 5) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 13 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 | 0 | 6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 7 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 7 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Atorvastatin 20 mg (Part A Period 1) | Midazolam 5 mg (Part A Period 2) | PF-06882961 Titration up to 120 mg BID (Part A Period 3) | PF-06882961 120 mg BID + Atorvastatin 20 mg (Part A Period 4) | PF-06882961 120 mg BID + Midazolam 5 mg (Part A Period 5) | PF-06882961 Titration up to 200 mg BID (Part A Period 6) | PF-06882961 200 mg BID + Atorvastatin 20 mg (Part A Period 7) | PF-06882961 200 mg BID + Midazolam 5 mg (Part A Period 8) | 0.15 mg LE & 0.03 mg EE (Part B Period 1) | PF-06882961 Titration up to 120 mg BID (Part B Period 2) | PF-06882961 120 mg BID + 0.15 mg LE & 0.03 mg EE (Part B Period 3) | PF-06882961 Titration up to 200 mg BID (Part B Period 4) | PF-06882961 200 mg BID + 0.15 mg LE & 0.03 mg EE (Part B Period 5) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 13 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 | 0 | 13 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Atorvastatin 20 mg (Part A Period 1) | Midazolam 5 mg (Part A Period 2) | PF-06882961 Titration up to 120 mg BID (Part A Period 3) | PF-06882961 120 mg BID + Atorvastatin 20 mg (Part A Period 4) | PF-06882961 120 mg BID + Midazolam 5 mg (Part A Period 5) | PF-06882961 Titration up to 200 mg BID (Part A Period 6) | PF-06882961 200 mg BID + Atorvastatin 20 mg (Part A Period 7) | PF-06882961 200 mg BID + Midazolam 5 mg (Part A Period 8) | 0.15 mg LE & 0.03 mg EE (Part B Period 1) | PF-06882961 Titration up to 120 mg BID (Part B Period 2) | PF-06882961 120 mg BID + 0.15 mg LE & 0.03 mg EE (Part B Period 3) | PF-06882961 Titration up to 200 mg BID (Part B Period 4) | PF-06882961 200 mg BID + 0.15 mg LE & 0.03 mg EE (Part B Period 5) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 5 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 5 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Atorvastatin 20 mg (Part A Period 1) | Midazolam 5 mg (Part A Period 2) | PF-06882961 Titration up to 120 mg BID (Part A Period 3) | PF-06882961 120 mg BID + Atorvastatin 20 mg (Part A Period 4) | PF-06882961 120 mg BID + Midazolam 5 mg (Part A Period 5) | PF-06882961 Titration up to 200 mg BID (Part A Period 6) | PF-06882961 200 mg BID + Atorvastatin 20 mg (Part A Period 7) | PF-06882961 200 mg BID + Midazolam 5 mg (Part A Period 8) | 0.15 mg LE & 0.03 mg EE (Part B Period 1) | PF-06882961 Titration up to 120 mg BID (Part B Period 2) | PF-06882961 120 mg BID + 0.15 mg LE & 0.03 mg EE (Part B Period 3) | PF-06882961 Titration up to 200 mg BID (Part B Period 4) | PF-06882961 200 mg BID + 0.15 mg LE & 0.03 mg EE (Part B Period 5) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 5 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 5 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Atorvastatin 20 mg (Part A Period 1) | Midazolam 5 mg (Part A Period 2) | PF-06882961 Titration up to 120 mg BID (Part A Period 3) | PF-06882961 120 mg BID + Atorvastatin 20 mg (Part A Period 4) | PF-06882961 120 mg BID + Midazolam 5 mg (Part A Period 5) | PF-06882961 Titration up to 200 mg BID (Part A Period 6) | PF-06882961 200 mg BID + Atorvastatin 20 mg (Part A Period 7) | PF-06882961 200 mg BID + Midazolam 5 mg (Part A Period 8) | 0.15 mg LE & 0.03 mg EE (Part B Period 1) | PF-06882961 Titration up to 120 mg BID (Part B Period 2) | PF-06882961 120 mg BID + 0.15 mg LE & 0.03 mg EE (Part B Period 3) | PF-06882961 Titration up to 200 mg BID (Part B Period 4) | PF-06882961 200 mg BID + 0.15 mg LE & 0.03 mg EE (Part B Period 5) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 6 | 0 | 0 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Atorvastatin 20 mg (Part A Period 1) | Midazolam 5 mg (Part A Period 2) | PF-06882961 Titration up to 120 mg BID (Part A Period 3) | PF-06882961 120 mg BID + Atorvastatin 20 mg (Part A Period 4) | PF-06882961 120 mg BID + Midazolam 5 mg (Part A Period 5) | PF-06882961 Titration up to 200 mg BID (Part A Period 6) | PF-06882961 200 mg BID + Atorvastatin 20 mg (Part A Period 7) | PF-06882961 200 mg BID + Midazolam 5 mg (Part A Period 8) | 0.15 mg LE & 0.03 mg EE (Part B Period 1) | PF-06882961 Titration up to 120 mg BID (Part B Period 2) | PF-06882961 120 mg BID + 0.15 mg LE & 0.03 mg EE (Part B Period 3) | PF-06882961 Titration up to 200 mg BID (Part B Period 4) | PF-06882961 200 mg BID + 0.15 mg LE & 0.03 mg EE (Part B Period 5) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 6 | 0 | 0 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 6 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Atorvastatin 20 mg (Part A Period 1) | Midazolam 5 mg (Part A Period 2) | PF-06882961 Titration up to 120 mg BID (Part A Period 3) | PF-06882961 120 mg BID + Atorvastatin 20 mg (Part A Period 4) | PF-06882961 120 mg BID + Midazolam 5 mg (Part A Period 5) | PF-06882961 Titration up to 200 mg BID (Part A Period 6) | PF-06882961 200 mg BID + Atorvastatin 20 mg (Part A Period 7) | PF-06882961 200 mg BID + Midazolam 5 mg (Part A Period 8) | 0.15 mg LE & 0.03 mg EE (Part B Period 1) | PF-06882961 Titration up to 120 mg BID (Part B Period 2) | PF-06882961 120 mg BID + 0.15 mg LE & 0.03 mg EE (Part B Period 3) | PF-06882961 Titration up to 200 mg BID (Part B Period 4) | PF-06882961 200 mg BID + 0.15 mg LE & 0.03 mg EE (Part B Period 5) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 17 | 0 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 16 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Protocol violation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Milestone | Atorvastatin 20 mg (Part A Period 1) | Midazolam 5 mg (Part A Period 2) | PF-06882961 Titration up to 120 mg BID (Part A Period 3) | PF-06882961 120 mg BID + Atorvastatin 20 mg (Part A Period 4) | PF-06882961 120 mg BID + Midazolam 5 mg (Part A Period 5) | PF-06882961 Titration up to 200 mg BID (Part A Period 6) | PF-06882961 200 mg BID + Atorvastatin 20 mg (Part A Period 7) | PF-06882961 200 mg BID + Midazolam 5 mg (Part A Period 8) | 0.15 mg LE & 0.03 mg EE (Part B Period 1) | PF-06882961 Titration up to 120 mg BID (Part B Period 2) | PF-06882961 120 mg BID + 0.15 mg LE & 0.03 mg EE (Part B Period 3) | PF-06882961 Titration up to 200 mg BID (Part B Period 4) | PF-06882961 200 mg BID + 0.15 mg LE & 0.03 mg EE (Part B Period 5) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 15 | 0 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 15 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Atorvastatin 20 mg (Part A Period 1) | Midazolam 5 mg (Part A Period 2) | PF-06882961 Titration up to 120 mg BID (Part A Period 3) | PF-06882961 120 mg BID + Atorvastatin 20 mg (Part A Period 4) | PF-06882961 120 mg BID + Midazolam 5 mg (Part A Period 5) | PF-06882961 Titration up to 200 mg BID (Part A Period 6) | PF-06882961 200 mg BID + Atorvastatin 20 mg (Part A Period 7) | PF-06882961 200 mg BID + Midazolam 5 mg (Part A Period 8) | 0.15 mg LE & 0.03 mg EE (Part B Period 1) | PF-06882961 Titration up to 120 mg BID (Part B Period 2) | PF-06882961 120 mg BID + 0.15 mg LE & 0.03 mg EE (Part B Period 3) | PF-06882961 Titration up to 200 mg BID (Part B Period 4) | PF-06882961 200 mg BID + 0.15 mg LE & 0.03 mg EE (Part B Period 5) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 16 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 14 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 |
| Milestone | Atorvastatin 20 mg (Part A Period 1) | Midazolam 5 mg (Part A Period 2) | PF-06882961 Titration up to 120 mg BID (Part A Period 3) | PF-06882961 120 mg BID + Atorvastatin 20 mg (Part A Period 4) | PF-06882961 120 mg BID + Midazolam 5 mg (Part A Period 5) | PF-06882961 Titration up to 200 mg BID (Part A Period 6) | PF-06882961 200 mg BID + Atorvastatin 20 mg (Part A Period 7) | PF-06882961 200 mg BID + Midazolam 5 mg (Part A Period 8) | 0.15 mg LE & 0.03 mg EE (Part B Period 1) | PF-06882961 Titration up to 120 mg BID (Part B Period 2) | PF-06882961 120 mg BID + 0.15 mg LE & 0.03 mg EE (Part B Period 3) | PF-06882961 Titration up to 200 mg BID (Part B Period 4) | PF-06882961 200 mg BID + 0.15 mg LE & 0.03 mg EE (Part B Period 5) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 15 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 14 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Milestone | Atorvastatin 20 mg (Part A Period 1) | Midazolam 5 mg (Part A Period 2) | PF-06882961 Titration up to 120 mg BID (Part A Period 3) | PF-06882961 120 mg BID + Atorvastatin 20 mg (Part A Period 4) | PF-06882961 120 mg BID + Midazolam 5 mg (Part A Period 5) | PF-06882961 Titration up to 200 mg BID (Part A Period 6) | PF-06882961 200 mg BID + Atorvastatin 20 mg (Part A Period 7) | PF-06882961 200 mg BID + Midazolam 5 mg (Part A Period 8) | 0.15 mg LE & 0.03 mg EE (Part B Period 1) | PF-06882961 Titration up to 120 mg BID (Part B Period 2) | PF-06882961 120 mg BID + 0.15 mg LE & 0.03 mg EE (Part B Period 3) | PF-06882961 Titration up to 200 mg BID (Part B Period 4) | PF-06882961 200 mg BID + 0.15 mg LE & 0.03 mg EE (Part B Period 5) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 14 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 12 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 |
| Milestone | Atorvastatin 20 mg (Part A Period 1) | Midazolam 5 mg (Part A Period 2) | PF-06882961 Titration up to 120 mg BID (Part A Period 3) | PF-06882961 120 mg BID + Atorvastatin 20 mg (Part A Period 4) | PF-06882961 120 mg BID + Midazolam 5 mg (Part A Period 5) | PF-06882961 Titration up to 200 mg BID (Part A Period 6) | PF-06882961 200 mg BID + Atorvastatin 20 mg (Part A Period 7) | PF-06882961 200 mg BID + Midazolam 5 mg (Part A Period 8) | 0.15 mg LE & 0.03 mg EE (Part B Period 1) | PF-06882961 Titration up to 120 mg BID (Part B Period 2) | PF-06882961 120 mg BID + 0.15 mg LE & 0.03 mg EE (Part B Period 3) | PF-06882961 Titration up to 200 mg BID (Part B Period 4) | PF-06882961 200 mg BID + 0.15 mg LE & 0.03 mg EE (Part B Period 5) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 13 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 11 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 |
| Milestone | Atorvastatin 20 mg (Part A Period 1) | Midazolam 5 mg (Part A Period 2) | PF-06882961 Titration up to 120 mg BID (Part A Period 3) | PF-06882961 120 mg BID + Atorvastatin 20 mg (Part A Period 4) | PF-06882961 120 mg BID + Midazolam 5 mg (Part A Period 5) | PF-06882961 Titration up to 200 mg BID (Part A Period 6) | PF-06882961 200 mg BID + Atorvastatin 20 mg (Part A Period 7) | PF-06882961 200 mg BID + Midazolam 5 mg (Part A Period 8) | 0.15 mg LE & 0.03 mg EE (Part B Period 1) | PF-06882961 Titration up to 120 mg BID (Part B Period 2) | PF-06882961 120 mg BID + 0.15 mg LE & 0.03 mg EE (Part B Period 3) | PF-06882961 Titration up to 200 mg BID (Part B Period 4) | PF-06882961 200 mg BID + 0.15 mg LE & 0.03 mg EE (Part B Period 5) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 12 | 0 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 9 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 |
| Milestone | Atorvastatin 20 mg (Part A Period 1) | Midazolam 5 mg (Part A Period 2) | PF-06882961 Titration up to 120 mg BID (Part A Period 3) | PF-06882961 120 mg BID + Atorvastatin 20 mg (Part A Period 4) | PF-06882961 120 mg BID + Midazolam 5 mg (Part A Period 5) | PF-06882961 Titration up to 200 mg BID (Part A Period 6) | PF-06882961 200 mg BID + Atorvastatin 20 mg (Part A Period 7) | PF-06882961 200 mg BID + Midazolam 5 mg (Part A Period 8) | 0.15 mg LE & 0.03 mg EE (Part B Period 1) | PF-06882961 Titration up to 120 mg BID (Part B Period 2) | PF-06882961 120 mg BID + 0.15 mg LE & 0.03 mg EE (Part B Period 3) | PF-06882961 Titration up to 200 mg BID (Part B Period 4) | PF-06882961 200 mg BID + 0.15 mg LE & 0.03 mg EE (Part B Period 5) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 11 | 0 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 10 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Milestone | Atorvastatin 20 mg (Part A Period 1) | Midazolam 5 mg (Part A Period 2) | PF-06882961 Titration up to 120 mg BID (Part A Period 3) | PF-06882961 120 mg BID + Atorvastatin 20 mg (Part A Period 4) | PF-06882961 120 mg BID + Midazolam 5 mg (Part A Period 5) | PF-06882961 Titration up to 200 mg BID (Part A Period 6) | PF-06882961 200 mg BID + Atorvastatin 20 mg (Part A Period 7) | PF-06882961 200 mg BID + Midazolam 5 mg (Part A Period 8) | 0.15 mg LE & 0.03 mg EE (Part B Period 1) | PF-06882961 Titration up to 120 mg BID (Part B Period 2) | PF-06882961 120 mg BID + 0.15 mg LE & 0.03 mg EE (Part B Period 3) | PF-06882961 Titration up to 200 mg BID (Part B Period 4) | PF-06882961 200 mg BID + 0.15 mg LE & 0.03 mg EE (Part B Period 5) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 9 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 9 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Atorvastatin 20 mg (Part A Period 1) | Midazolam 5 mg (Part A Period 2) | PF-06882961 Titration up to 120 mg BID (Part A Period 3) | PF-06882961 120 mg BID + Atorvastatin 20 mg (Part A Period 4) | PF-06882961 120 mg BID + Midazolam 5 mg (Part A Period 5) | PF-06882961 Titration up to 200 mg BID (Part A Period 6) | PF-06882961 200 mg BID + Atorvastatin 20 mg (Part A Period 7) | PF-06882961 200 mg BID + Midazolam 5 mg (Part A Period 8) | 0.15 mg LE & 0.03 mg EE (Part B Period 1) | PF-06882961 Titration up to 120 mg BID (Part B Period 2) | PF-06882961 120 mg BID + 0.15 mg LE & 0.03 mg EE (Part B Period 3) | PF-06882961 Titration up to 200 mg BID (Part B Period 4) | PF-06882961 200 mg BID + 0.15 mg LE & 0.03 mg EE (Part B Period 5) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 9 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 9 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Atorvastatin was given on Day 1 in Periods 1, 4 and 7 of Part A and blood samples were collected for atorvastatin pharmacokinetic (PK) at the preset time points described in the Time Frame. AUCinf calculated area under the plasma concentration-time profile from time 0 extrapolated to infinite time.
| nanogram*hour/milliliter (ng*hr/mL) | Atorvastatin 20 mg (Part A Period 1) | PF-06882961 120 mg BID + Atorvastatin 20 mg (Part A Period 4) | PF-06882961 200 mg BID + Atorvastatin 20 mg (Part A Period 7) |
|---|---|---|---|
| (Part A) Area Under the Concentration-time Curve From Time 0 to Infinity (AUCinf) of Atorvastatin in Periods 1, 4, and 7 | 32.27 ± 41 | 46.94 ± 72 | 54.43 ± 22 |
Midazolam was given on Day 1 in Periods 2, 5 and 8 of Part A and blood samples were collected for midazolam PK at the preset time points described in the Time Frame. AUCinf calculated area under the plasma concentration-time profile from time 0 extrapolated to infinite time.
| ng*hr/mL | Midazolam 5 mg (Part A Period 2) | PF-06882961 120 mg BID + Midazolam 5 mg (Part A Period 5) | PF-06882961 200 mg BID + Midazolam 5 mg (Part A Period 8) |
|---|---|---|---|
| (Part A) AUCinf of Midazolam in Periods 2, 5, and 8 | 70.53 ± 32 | 58.81 ± 40 | 49.78 ± 22 |
Levonorgestrel was given on Day 1 in Periods 1, 3 and 5 of Part B and blood samples were collected for levonorgestrel PK at the preset time points described in the Time Frame. AUCinf calculated area under the plasma concentration-time profile from time 0 extrapolated to infinite time.
| picogram*hour/milliliter (pg*hr/mL) | 0.15 mg LE & 0.03 mg EE (Part B Period 1) | PF-06882961 120 mg BID + 0.15 mg LE & 0.03 mg EE (Part B Period 3) | PF-06882961 200 mg BID + 0.15 mg LE & 0.03 mg EE (Part B Period 5) |
|---|---|---|---|
| (Part B) AUCinf of Levonorgestrel in Periods 1, 3 and 5 | 48800 ± 42 | 62330 ± 61 | 66490 ± 57 |
Ethinyl estradiol (EE) was given on Day 1 in Periods 1, 3 and 5 of Part B and blood samples were collected for ethinyl estradiol PK at the preset time points described in the Time Frame. AUCinf calculated area under the plasma concentration-time profile from time 0 extrapolated to infinite time.
| pg*hr/mL | 0.15 mg LE & 0.03 mg EE (Part B Period 1) | PF-06882961 120 mg BID + 0.15 mg LE & 0.03 mg EE (Part B Period 3) | PF-06882961 200 mg BID + 0.15 mg LE & 0.03 mg EE (Part B Period 5) |
|---|---|---|---|
| (Part B) AUCinf of Ethinyl Estradiol in Periods 1, 3 and 5 | 772.1 ± 41 | 723.5 ± 24 | 604.4 ± 33 |
An AE was any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An serious adverse event was defined as any untoward medical occurrence that,at any dose:resulted in death;was life-threatening;required inpatient hospitalization or prolongation of existing hospitalization;resulted in persistent disability/incapacity; was a congenital anomaly/birth defect;or other serious situations such as important medical events. The investigator was required to use clinical judgment to assess the potential relationship between investigational product and each AE, to define an treatment-related AE.
| Participants | Atorvastatin 20 mg (Part A Period 1) | Midazolam 5 mg (Part A Period 2) | PF-06882961 Titration up to 120 mg BID (Part A Period 3) | PF-06882961 120 mg BID + Atorvastatin 20 mg (Part A Period 4) | PF-06882961 120 mg BID + Midazolam 5 mg (Part A Period 5) | PF-06882961 Titration up to 200 mg BID (Part A Period 6) | PF-06882961 200 mg BID + Atorvastatin 20 mg (Part A Period 7) | PF-06882961 200 mg BID + Midazolam 5 mg (Part A Period 8) |
|---|---|---|---|---|---|---|---|---|
| Participants with adverse events | 2 | 3 | 13 | 5 | 4 | 12 | 5 | 2 |
| Participants with serious adverse events | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Participants with severe adverse events | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Participants discontinued from study due to AEs | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Participants discontinued study drug due to AE and continue study | 0 | 0 | 2 | 0 | 0 | 7 | 0 | 1 |
| Participants with dose reduced or temporary discontinuation due to AE | 0 | 0 | 1 | 0 | 0 | 4 | 0 | 0 |
An AE was any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An serious adverse event was defined as any untoward medical occurrence that,at any dose:resulted in death;was life-threatening;required inpatient hospitalization or prolongation of existing hospitalization;resulted in persistent disability/incapacity; was a congenital anomaly/birth defect;or other serious situations such as important medical events. The investigator was required to use clinical judgment to assess the potential relationship between investigational product and each AE, to define an treatment-related AE.
| Participants | 0.15 mg LE & 0.03 mg EE (Part B Period 1) | PF-06882961 Titration up to 120 mg BID (Part B Period 2) | PF-06882961 120 mg BID + 0.15 mg LE & 0.03 mg EE (Part B Period 3) | PF-06882961 Titration up to 200 mg BID (Part B Period 4) | PF-06882961 200 mg BID + 0.15 mg LE & 0.03 mg EE (Part B Period 5) |
|---|---|---|---|---|---|
| Participants with adverse events | 5 | 15 | 7 | 12 | 7 |
| Participants with serious adverse events | 0 | 0 | 0 | 0 | 0 |
| Participants with severe adverse events | 0 | 0 | 0 | 0 | 0 |
| Participants discontinued from study due to AEs | 0 | 0 | 0 | 0 | 0 |
| Participants discontinued study drug due to AE and continue study | 0 | 2 | 2 | 2 | 0 |
| Participants with dose reduced or temporary discontinuation due to AE | 0 | 2 | 0 | 2 | 0 |
Laboratory tests (including hematology, clinical chemistry, urinalysis) were reported and abnormalities were defined for laboratory values that met specific criteria.
| Participants | Atorvastatin 20 mg (Part A Period 1) | Midazolam 5 mg (Part A Period 2) | PF-06882961 Titration up to 120 mg BID (Part A Period 3) | PF-06882961 120 mg BID + Atorvastatin 20 mg (Part A Period 4) | PF-06882961 120 mg BID + Midazolam 5 mg (Part A Period 5) | PF-06882961 Titration up to 200 mg BID (Part A Period 6) | PF-06882961 200 mg BID + Atorvastatin 20 mg (Part A Period 7) | PF-06882961 200 mg BID + Midazolam 5 mg (Part A Period 8) |
|---|---|---|---|---|---|---|---|---|
| (Part A) Number of Participants With Clinical Laboratory Abnormalities During Part A of the Study (Without Regard to Baseline Abnormality) | 0 | 15 | 16 | 2 | 5 | 12 | 0 | 6 |
Laboratory tests (including hematology, clinical chemistry, urinalysis) were reported and abnormalities were defined for laboratory values that met specific criteria.
| Participants | 0.15 mg LE & 0.03 mg EE (Part B Period 1) | PF-06882961 Titration up to 120 mg BID (Period 2) | PF-06882961 120 mg BID + 0.15 mg LE & 0.03 mg EE (Part B Period 3) | PF-06882961 Titration up to 200 mg BID (Part B Period 4) | PF-06882961 200 mg BID + 0.15 mg LE & 0.03 mg EE (Part B Period 5) |
|---|---|---|---|---|---|
| (Part B) Number of Participants With Clinical Laboratory Abnormalities During Part B of the Study (Without Regard to Baseline Abnormality) | 17 | 16 | 2 | 12 | 9 |
Supine blood pressure (mm Hg) and pulse rate (beats per minute) were measured. Supine BP was measured with the participant's arm supported at heart level and recorded to the nearest mmHg after approximately 5 minutes of rest.
| Participants | Atorvastatin 20 mg (Part A Period 1) | Midazolam 5 mg (Part A Period 2) | PF-06882961 Titration up to 120 mg BID (Part A Period 3) | PF-06882961 120 mg BID + Atorvastatin 20 mg (Part A Period 4) | PF-06882961 120 mg BID + Midazolam 5 mg (Part A Period 5) | PF-06882961 Titration up to 200 mg BID (Part A Period 6) | PF-06882961 200 mg BID + Atorvastatin 20 mg (Part A Period 7) | PF-06882961 200 mg BID + Midazolam 5 mg (Part A Period 8) |
|---|---|---|---|---|---|---|---|---|
| Supine systolic blood pressure (SBP) value <90 mm Hg | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Supine SBP change >=30 mm Hg increase | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Supine SBP change >=30 mm Hg decrease | 0 | 0 | 1 | 2 | 1 | 1 | 1 | 1 |
| Supine diastolic blood pressure (DBP) value <50 mm Hg | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Supine DBP >= 20 mm Hg increase | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Supine DBP >= 20 mm Hg decrease | 1 | 1 | 2 | 2 | 3 | 1 | 2 | 1 |
| Pulse rate value <40 bpm | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Pulse rate value >120 bpm | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Supine blood pressure (mm Hg) and pulse rate (bpm) were measured. Supine BP was measured with the participant's arm supported at heart level and recorded to the nearest mmHg after approximately 5 minutes of rest.
| Participants | 0.15 mg LE & 0.03 mg EE (Part B Period 1) | PF-06882961 Titration up to 120 mg BID (Part B Period 2) | PF-06882961 120 mg BID + 0.15 mg LE & 0.03 mg EE (Part B Period 3) | PF-06882961 Titration up to 200 mg BID (Part B Period 4) | PF-06882961 200 mg BID + 0.15 mg LE & 0.03 mg EE (Part B Period 5) |
|---|---|---|---|---|---|
| Supine SBP value <90 mm Hg | 0 | 0 | 0 | 0 | 0 |
| Supine SBP change >=30 mm Hg increase | 0 | 0 | 0 | 0 | 0 |
| Supine SBP change >=30 mm Hg decrease | 1 | 1 | 0 | 1 | 1 |
| Supine DBP value <50 mm Hg | 0 | 0 | 0 | 0 | 0 |
| Supine DBP >= 20 mm Hg increase | 0 | 0 | 0 | 0 | 0 |
| Supine DBP >= 20 mm Hg decrease | 1 | 3 | 0 | 1 | 1 |
| Pulse rate value <40 bpm | 0 | 0 | 0 | 0 | 0 |
| Pulse rate value >120 bpm | 0 | 0 | 0 | 0 | 0 |
Percentage of changes from Baseline in body weight of the participants were measured.
| percentage | All Participants in Part A |
|---|---|
| Baseline 1 - Period 8 Day 2 / PF-06882961 200 mg BID + Midazolam 5 mg | -9.04 ± 3.539 |
| Baseline 2 - Period 8 Day 2 / PF-06882961 200 mg BID + Midazolam 5 mg | -9.30 ± 4.159 |
Percentage of changes from Baseline in body weight of the participants were measured.
| percentage | All Participants in Part B |
|---|---|
| Baseline 1 - Period 5 Day 6 / PF-06882961 200 mg BID + 0.15 mg LE & 0.03 mg EE | -8.77 ± 2.190 |
| Baseline 2 - Period 5 Day 6 / PF-06882961 200 mg BID + 0.15 mg LE & 0.03 mg EE | -5.40 ± 1.503 |
Standard 12-lead ECGs utilizing limb leads were collected using an ECG machine that automatically calculated the heart rate and measured PR, QT, and QT interval corrected for heart rate (QTc) and QRS complex.
| Participants | Atorvastatin 20 mg (Part A Period 1) | Midazolam 5 mg (Part A Period 2) | PF-06882961 Titration up to 120 mg BID (Part A Period 3) | PF-06882961 120 mg BID + Atorvastatin 20 mg (Part A Period 4) | PF-06882961 120 mg BID + Midazolam 5 mg (Part A Period 5) | PF-06882961 Titration up to 200 mg BID (Part A Period 6) | PF-06882961 200 mg BID + Atorvastatin 20 mg (Part A Period 7) | PF-06882961 200 mg BID + Midazolam 5 mg (Part A Period 8) |
|---|---|---|---|---|---|---|---|---|
| PR interval value >=300 msec | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| PR interval %change >=25/50% msec | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| QRS interval value >= 140 msec | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| QRS interval %change >=50% msec | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| QTcF 450 msec < value <=480 msec | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| QTcF 480 msec < value <=500 msec | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| QTcF value >500 msec | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| QTcF 30 msec < change <=60 msec | 0 | 0 | 1 | 2 | 0 | 1 | 0 | 1 |
| QTcF change >60 msec | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Standard 12-lead ECGs utilizing limb leads were collected using an ECG machine that automatically calculated the heart rate and measured PR, QT, and QT interval corrected for heart rate (QTc) and QRS complex.
| Participants | 0.15 mg LE & 0.03 mg EE (Part B Period 1) | PF-06882961 Titration up to 120 mg BID (Part B Period 2) | PF-06882961 120 mg BID + 0.15 mg LE & 0.03 mg EE (Part B Period 3) | PF-06882961 Titration up to 200 mg BID (Part B Period 4) | PF-06882961 200 mg BID + 0.15 mg LE & 0.03 mg EE (Part B Period 5) |
|---|---|---|---|---|---|
| PR interval value >=300 msec | 0 | 0 | 0 | 0 | 0 |
| PR interval %change >=25/50% msec | 0 | 0 | 0 | 0 | 0 |
| QRS interval value >= 140 msec | 0 | 0 | 0 | 0 | 0 |
| QRS interval %change >=50% msec | 0 | 0 | 0 | 0 | 0 |
| QTcF 450 msec < value <=480 msec | 0 | 0 | 0 | 1 | 0 |
| QTcF 480 msec < value <=500 msec | 0 | 0 | 0 | 0 | 0 |
| QTcF value >500 msec | 0 | 0 | 0 | 0 | 0 |
| QTcF 30 msec < change <=60 msec | 0 | 0 | 0 | 0 | 0 |
| QTcF change >60 msec | 0 | 0 | 0 | 0 | 0 |
The C-SSRS was an interview-based rating scale to systematically assess suicidal ideation and suicidal behavior. C-SSRS assessed whether participant experienced any of the following 1: completed suicide, 2: suicide attempt (response of "yes" on "actual attempt"), 3: preparatory acts toward imminent suicidal behavior ("yes" on "aborted attempt", "interrupted attempt", "preparatory acts or behavior"), 4: any suicidal behavior or ideation, suicidal ideation ("yes" on "wish to be dead", "non-specific active suicidal thoughts"), 7: self-injurious behavior, no suicidal intent ("yes" on "has participant engaged in non-suicidal self-injurious behavior").
| Participants | All Participants in Part A |
|---|---|
| Period 1 Day -1 / Atorvastatin 20 mg | 0 |
| Period 1 Day -1 / Atorvastatin 20 mg Past 12 Months | 0 |
| Period 3 Day 1 / PF-06882961 titration up to 120 mg BID (Since Last Visit) | 0 |
| Period 3 Day 8 / PF-06882961 titration up to 120 mg BID (Since Last Visit) | 0 |
| Period 3 Day 15 / PF-06882961 titration up to 120 mg BID (Since Last Visit) | 0 |
| Period 3 Day 23 / PF-06882961 titration up to 120 mg BID (Since Last Visit) | 0 |
| Period 4 Day 1 / PF-06882961 120 mg BID + Atorvastatin 20 mg (Since Last Visit) | 0 |
| Period 6 Day 1 / PF-06882961 titration up to 200 mg BID (Since Last Visit) | 0 |
| Period 6 Day 9 / PF-06882961 titration up to 200 mg BID (Since Last Visit) | 0 |
| Period 6 Day 19 / PF-06882961 titration up to 200 mg BID (Since Last Visit) | 0 |
| Period 8 Day 1 / PF-06882961 200 mg BID + Midazolam 5 mg (Since Last Visit) | 0 |
| Follow Up (Since Last Visit) | 0 |
The C-SSRS was an interview-based rating scale to systematically assess suicidal ideation and suicidal behavior. C-SSRS assessed whether participant experienced any of the following 1: completed suicide, 2: suicide attempt (response of "yes" on "actual attempt"), 3: preparatory acts toward imminent suicidal behavior ("yes" on "aborted attempt", "interrupted attempt", "preparatory acts or behavior"), 4: any suicidal behavior or ideation, suicidal ideation ("yes" on "wish to be dead", "non-specific active suicidal thoughts"), 7: self-injurious behavior, no suicidal intent ("yes" on "has participant engaged in non-suicidal self-injurious behavior").
| Participants | All Participants in Part B |
|---|---|
| Period 1 Day -1 / 0.15 mg LE & 0.03 mg EE | 0 |
| Period 1 Day -1 / 0.15 mg LE & 0.03 mg EE (Past 12 months) | 0 |
| Period 2 Day 1 / PF-06882961 titration up to 120 mg BID (Since Last Visit) | 0 |
| Period 2 Day 8 / PF-06882961 titration up to 120 mg BID (Since Last Visit) | 0 |
| Period 2 Day 15 / PF-06882961 titration up to 120 mg BID (Since Last Visit) | 0 |
| Period 2 Day 22 / PF-06882961 titration up to 120 mg BID (Since Last Visit) | 0 |
| Period 3 Day 1 / PF-06882961 120 mg BID + 0.15 mg LE & 0.03 mg EE (Since Last Visit) | 0 |
| Period 4 Day 1 / PF-06882961 titration up to 200 mg BID (Since Last Visit) | 0 |
| Period 4 Day 9 / PF-06882961 titration up to 200 mg BID (Since Last Visit) | 0 |
| Period 4 Day 19 / PF-06882961 titration up to 200 mg BID (Since Last Visit) | 0 |
| Period 5 Day 6 / PF-06882961 200 mg BID + 0.15 mg LE & 0.03 mg EE (Since Last Visit) | 0 |
| Follow Up (Since Last Visit) | 0 |
The PHQ-9 is a 9 item self-report scale for the assessment of depressive symptoms. The questions included "little interest/pleasure in things", "feeling down depressed or hopeless", "trouble falling or staying asleep", "feeling tired or little energy", "poor appetite or overeating", "feeling bad about yourself", "trouble concentrating on things", "moving slowly or fidgety/restless" and "thoughts you be better off dead". Each item was scored on scale of "not at all", "several days", "more than half the days" to "nearly every day". Total score range: 0-27 (each item with scale from 0 \[not at all\] to 3 \[nearly every day\]. Higher score=greater severity).
| Participants | All Participants in Part A |
|---|---|
| Period 1 Day -1 / Atorvastatin 20 mg / Little Interest/Pleasure in Things — Not At All | 18 |
| Period 1 Day -1 / Atorvastatin 20 mg / Little Interest/Pleasure in Things — Several Days | 0 |
| Period 1 Day -1 / Atorvastatin 20 mg / Little Interest/Pleasure in Things — More Than Half The Days | 0 |
| Period 1 Day -1 / Atorvastatin 20 mg / Little Interest/Pleasure in Things — Nearly Every Day | 0 |
| Period 1 Day -1 / Atorvastatin 20 mg / Feeling Down Depressed or Hopeless — Not At All | 18 |
| Period 1 Day -1 / Atorvastatin 20 mg / Feeling Down Depressed or Hopeless — Several Days | 0 |
| Period 1 Day -1 / Atorvastatin 20 mg / Feeling Down Depressed or Hopeless — More Than Half The Days | 0 |
| Period 1 Day -1 / Atorvastatin 20 mg / Feeling Down Depressed or Hopeless — Nearly Every Day | 0 |
| Period 1 Day -1 / Atorvastatin 20 mg / Trouble Falling or Staying Asleep — Not At All | 18 |
| Period 1 Day -1 / Atorvastatin 20 mg / Trouble Falling or Staying Asleep — Several Days | 0 |
| Period 1 Day -1 / Atorvastatin 20 mg / Trouble Falling or Staying Asleep — More Than Half The Days | 0 |
| Period 1 Day -1 / Atorvastatin 20 mg / Trouble Falling or Staying Asleep — Nearly Every Day | 0 |
| Period 1 Day -1 / Atorvastatin 20 mg / Feeling Tired or Little Energy — Not At All | 18 |
| Period 1 Day -1 / Atorvastatin 20 mg / Feeling Tired or Little Energy — Several Days | 0 |
| Period 1 Day -1 / Atorvastatin 20 mg / Feeling Tired or Little Energy — More Than Half The Days | 0 |
| Period 1 Day -1 / Atorvastatin 20 mg / Feeling Tired or Little Energy — Nearly Every Day | 0 |
| Period 1 Day -1 / Atorvastatin 20 mg / Poor Appetite or Overeating — Not At All | 18 |
| Period 1 Day -1 / Atorvastatin 20 mg / Poor Appetite or Overeating — Several Days | 0 |
| Period 1 Day -1 / Atorvastatin 20 mg / Poor Appetite or Overeating — More Than Half The Days | 0 |
| Period 1 Day -1 / Atorvastatin 20 mg / Poor Appetite or Overeating — Nearly Every Day | 0 |
| Period 1 Day -1 / Atorvastatin 20 mg / Feeling Bad About Yourself — Not At All | 18 |
| Period 1 Day -1 / Atorvastatin 20 mg / Feeling Bad About Yourself — Several Days | 0 |
| Period 1 Day -1 / Atorvastatin 20 mg / Feeling Bad About Yourself — More Than Half The Days | 0 |
| Period 1 Day -1 / Atorvastatin 20 mg / Feeling Bad About Yourself — Nearly Every Day | 0 |
| Period 1 Day -1 / Atorvastatin 20 mg / Trouble Concentrating on Things — Not At All | 18 |
| Period 1 Day -1 / Atorvastatin 20 mg / Trouble Concentrating on Things — Several Days | 0 |
| Period 1 Day -1 / Atorvastatin 20 mg / Trouble Concentrating on Things — More Than Half The Days | 0 |
| Period 1 Day -1 / Atorvastatin 20 mg / Trouble Concentrating on Things — Nearly Every Day | 0 |
| Period 1 Day -1 / Atorvastatin 20 mg / Moving Slowly or Fidgety/Restless — Not At All | 18 |
| Period 1 Day -1 / Atorvastatin 20 mg / Moving Slowly or Fidgety/Restless — Several Days | 0 |
| Period 1 Day -1 / Atorvastatin 20 mg / Moving Slowly or Fidgety/Restless — More Than Half The Days | 0 |
| Period 1 Day -1 / Atorvastatin 20 mg / Moving Slowly or Fidgety/Restless — Nearly Every Day | 0 |
| Period 1 Day -1 / Atorvastatin 20 mg / Thoughts You Be Better Off Dead — Not At All | 18 |
| Period 1 Day -1 / Atorvastatin 20 mg / Thoughts You Be Better Off Dead — Several Days | 0 |
| Period 1 Day -1 / Atorvastatin 20 mg / Thoughts You Be Better Off Dead — More Than Half The Days | 0 |
| Period 1 Day -1 / Atorvastatin 20 mg / Thoughts You Be Better Off Dead — Nearly Every Day | 0 |
| Period 3 Day 1 / PF-06882961 titration up to 120 mg BID / Little Interest/Pleasure in Things — Not At All | 17 |
| Period 3 Day 1 / PF-06882961 titration up to 120 mg BID / Little Interest/Pleasure in Things — Several Days | 0 |
| Period 3 Day 1 / PF-06882961 titration up to 120 mg BID / Little Interest/Pleasure in Things — More Than Half The Days | 0 |
| Period 3 Day 1 / PF-06882961 titration up to 120 mg BID / Little Interest/Pleasure in Things — Nearly Every Day | 0 |
| Period 3 Day 1 / PF-06882961 titration up to 120 mg BID / Feeling Down Depressed or Hopeless — Not At All | 17 |
| Period 3 Day 1 / PF-06882961 titration up to 120 mg BID / Feeling Down Depressed or Hopeless — Several Days | 0 |
| Period 3 Day 1 / PF-06882961 titration up to 120 mg BID / Feeling Down Depressed or Hopeless — More Than Half The Days | 0 |
| Period 3 Day 1 / PF-06882961 titration up to 120 mg BID / Feeling Down Depressed or Hopeless — Nearly Every Day | 0 |
| Period 3 Day 1 / PF-06882961 titration up to 120 mg BID / Trouble Falling or Staying Asleep — Not At All | 17 |
| Period 3 Day 1 / PF-06882961 titration up to 120 mg BID / Trouble Falling or Staying Asleep — Several Days | 0 |
| Period 3 Day 1 / PF-06882961 titration up to 120 mg BID / Trouble Falling or Staying Asleep — More Than Half The Days | 0 |
| Period 3 Day 1 / PF-06882961 titration up to 120 mg BID / Trouble Falling or Staying Asleep — Nearly Every Day | 0 |
| Period 3 Day 1 / PF-06882961 titration up to 120 mg BID / Feeling Tired or Little Energy — Not At All | 17 |
| Period 3 Day 1 / PF-06882961 titration up to 120 mg BID / Feeling Tired or Little Energy — Several Days | 0 |
| Period 3 Day 1 / PF-06882961 titration up to 120 mg BID / Feeling Tired or Little Energy — More Than Half The Days | 0 |
| Period 3 Day 1 / PF-06882961 titration up to 120 mg BID / Feeling Tired or Little Energy — Nearly Every Day | 0 |
| Period 3 Day 1 / PF-06882961 titration up to 120 mg BID / Poor Appetite or Overeating — Not At All | 17 |
| Period 3 Day 1 / PF-06882961 titration up to 120 mg BID / Poor Appetite or Overeating — Several Days | 0 |
| Period 3 Day 1 / PF-06882961 titration up to 120 mg BID / Poor Appetite or Overeating — More Than Half The Days | 0 |
| Period 3 Day 1 / PF-06882961 titration up to 120 mg BID / Poor Appetite or Overeating — Nearly Every Day | 0 |
| Period 3 Day 1 / PF-06882961 titration up to 120 mg BID / Feeling Bad About Yourself — Not At All | 17 |
| Period 3 Day 1 / PF-06882961 titration up to 120 mg BID / Feeling Bad About Yourself — Several Days | 0 |
| Period 3 Day 1 / PF-06882961 titration up to 120 mg BID / Feeling Bad About Yourself — More Than Half The Days | 0 |
| Period 3 Day 1 / PF-06882961 titration up to 120 mg BID / Feeling Bad About Yourself — Nearly Every Day | 0 |
| Period 3 Day 1 / PF-06882961 titration up to 120 mg BID / Trouble Concentrating on Things — Not At All | 17 |
| Period 3 Day 1 / PF-06882961 titration up to 120 mg BID / Trouble Concentrating on Things — Several Days | 0 |
| Period 3 Day 1 / PF-06882961 titration up to 120 mg BID / Trouble Concentrating on Things — More Than Half The Days | 0 |
| Period 3 Day 1 / PF-06882961 titration up to 120 mg BID / Trouble Concentrating on Things — Nearly Every Day | 0 |
| Period 3 Day 1 / PF-06882961 titration up to 120 mg BID / Moving Slowly or Fidgety/Restless — Not At All | 17 |
| Period 3 Day 1 / PF-06882961 titration up to 120 mg BID / Moving Slowly or Fidgety/Restless — Several Days | 0 |
| Period 3 Day 1 / PF-06882961 titration up to 120 mg BID / Moving Slowly or Fidgety/Restless — More Than Half The Days | 0 |
| Period 3 Day 1 / PF-06882961 titration up to 120 mg BID / Moving Slowly or Fidgety/Restless — Nearly Every Day | 0 |
| Period 3 Day 1 / PF-06882961 titration up to 120 mg BID / Thoughts You Be Better Off Dead — Not At All | 17 |
| Period 3 Day 1 / PF-06882961 titration up to 120 mg BID / Thoughts You Be Better Off Dead — Several Days | 0 |
| Period 3 Day 1 / PF-06882961 titration up to 120 mg BID / Thoughts You Be Better Off Dead — More Than Half The Days | 0 |
| Period 3 Day 1 / PF-06882961 titration up to 120 mg BID / Thoughts You Be Better Off Dead — Nearly Every Day | 0 |
| Period 3 Day 8 / PF-06882961 titration up to 120 mg BID / Little Interest/Pleasure in Things — Not At All | 16 |
| Period 3 Day 8 / PF-06882961 titration up to 120 mg BID / Little Interest/Pleasure in Things — Several Days | 0 |
| Period 3 Day 8 / PF-06882961 titration up to 120 mg BID / Little Interest/Pleasure in Things — More Than Half The Days | 0 |
| Period 3 Day 8 / PF-06882961 titration up to 120 mg BID / Little Interest/Pleasure in Things — Nearly Every Day | 0 |
| Period 3 Day 8 / PF-06882961 titration up to 120 mg BID / Feeling Down Depressed or Hopeless — Not At All | 16 |
| Period 3 Day 8 / PF-06882961 titration up to 120 mg BID / Feeling Down Depressed or Hopeless — Several Days | 0 |
| Period 3 Day 8 / PF-06882961 titration up to 120 mg BID / Feeling Down Depressed or Hopeless — More Than Half The Days | 0 |
| Period 3 Day 8 / PF-06882961 titration up to 120 mg BID / Feeling Down Depressed or Hopeless — Nearly Every Day | 0 |
| Period 3 Day 8 / PF-06882961 titration up to 120 mg BID / Trouble Falling or Staying Asleep — Not At All | 16 |
| Period 3 Day 8 / PF-06882961 titration up to 120 mg BID / Trouble Falling or Staying Asleep — Several Days | 0 |
| Period 3 Day 8 / PF-06882961 titration up to 120 mg BID / Trouble Falling or Staying Asleep — More Than Half The Days | 0 |
| Period 3 Day 8 / PF-06882961 titration up to 120 mg BID / Trouble Falling or Staying Asleep — Nearly Every Day | 0 |
| Period 3 Day 8 / PF-06882961 titration up to 120 mg BID / Feeling Tired or Little Energy — Not At All | 16 |
| Period 3 Day 8 / PF-06882961 titration up to 120 mg BID / Feeling Tired or Little Energy — Several Days | 0 |
| Period 3 Day 8 / PF-06882961 titration up to 120 mg BID / Feeling Tired or Little Energy — More Than Half The Days | 0 |
| Period 3 Day 8 / PF-06882961 titration up to 120 mg BID / Feeling Tired or Little Energy — Nearly Every Day | 0 |
| Period 3 Day 8 / PF-06882961 titration up to 120 mg BID / Poor Appetite or Overeating — Not At All | 15 |
| Period 3 Day 8 / PF-06882961 titration up to 120 mg BID / Poor Appetite or Overeating — Several Days | 1 |
| Period 3 Day 8 / PF-06882961 titration up to 120 mg BID / Poor Appetite or Overeating — More Than Half The Days | 0 |
| Period 3 Day 8 / PF-06882961 titration up to 120 mg BID / Poor Appetite or Overeating — Nearly Every Day | 0 |
| Period 3 Day 8 / PF-06882961 titration up to 120 mg BID / Feeling Bad About Yourself — Not At All | 16 |
| Period 3 Day 8 / PF-06882961 titration up to 120 mg BID / Feeling Bad About Yourself — Several Days | 0 |
| Period 3 Day 8 / PF-06882961 titration up to 120 mg BID / Feeling Bad About Yourself — More Than Half The Days | 0 |
| Period 3 Day 8 / PF-06882961 titration up to 120 mg BID / Feeling Bad About Yourself — Nearly Every Day | 0 |
| Period 3 Day 8 / PF-06882961 titration up to 120 mg BID / Trouble Concentrating on Things — Not At All | 16 |
| Period 3 Day 8 / PF-06882961 titration up to 120 mg BID / Trouble Concentrating on Things — Several Days | 0 |
| Period 3 Day 8 / PF-06882961 titration up to 120 mg BID / Trouble Concentrating on Things — More Than Half The Days | 0 |
| Period 3 Day 8 / PF-06882961 titration up to 120 mg BID / Trouble Concentrating on Things — Nearly Every Day | 0 |
| Period 3 Day 8 / PF-06882961 titration up to 120 mg BID / Moving Slowly or Fidgety/Restless — Not At All | 16 |
| Period 3 Day 8 / PF-06882961 titration up to 120 mg BID / Moving Slowly or Fidgety/Restless — Several Days | 0 |
| Period 3 Day 8 / PF-06882961 titration up to 120 mg BID / Moving Slowly or Fidgety/Restless — More Than Half The Days | 0 |
| Period 3 Day 8 / PF-06882961 titration up to 120 mg BID / Moving Slowly or Fidgety/Restless — Nearly Every Day | 0 |
| Period 3 Day 8 / PF-06882961 titration up to 120 mg BID / Thoughts You Be Better Off Dead — Not At All | 16 |
| Period 3 Day 8 / PF-06882961 titration up to 120 mg BID / Thoughts You Be Better Off Dead — Several Days | 0 |
| Period 3 Day 8 / PF-06882961 titration up to 120 mg BID / Thoughts You Be Better Off Dead — More Than Half The Days | 0 |
| Period 3 Day 8 / PF-06882961 titration up to 120 mg BID / Thoughts You Be Better Off Dead — Nearly Every Day | 0 |
| Period 3 Day 15 / PF-06882961 titration up to 120 mg BID / Little Interest/Pleasure in Things — Not At All | 16 |
| Period 3 Day 15 / PF-06882961 titration up to 120 mg BID / Little Interest/Pleasure in Things — Several Days | 0 |
| Period 3 Day 15 / PF-06882961 titration up to 120 mg BID / Little Interest/Pleasure in Things — More Than Half The Days | 0 |
| Period 3 Day 15 / PF-06882961 titration up to 120 mg BID / Little Interest/Pleasure in Things — Nearly Every Day | 0 |
| Period 3 Day 15 / PF-06882961 titration up to 120 mg BID / Feeling Down Depressed or Hopeless — Not At All | 16 |
| Period 3 Day 15 / PF-06882961 titration up to 120 mg BID / Feeling Down Depressed or Hopeless — Several Days | 0 |
| Period 3 Day 15 / PF-06882961 titration up to 120 mg BID / Feeling Down Depressed or Hopeless — More Than Half The Days | 0 |
| Period 3 Day 15 / PF-06882961 titration up to 120 mg BID / Feeling Down Depressed or Hopeless — Nearly Every Day | 0 |
| Period 3 Day 15 / PF-06882961 titration up to 120 mg BID / Trouble Falling or Staying Asleep — Not At All | 16 |
| Period 3 Day 15 / PF-06882961 titration up to 120 mg BID / Trouble Falling or Staying Asleep — Several Days | 0 |
| Period 3 Day 15 / PF-06882961 titration up to 120 mg BID / Trouble Falling or Staying Asleep — More Than Half The Days | 0 |
| Period 3 Day 15 / PF-06882961 titration up to 120 mg BID / Trouble Falling or Staying Asleep — Nearly Every Day | 0 |
| Period 3 Day 15 / PF-06882961 titration up to 120 mg BID / Feeling Tired or Little Energy — Not At All | 16 |
| Period 3 Day 15 / PF-06882961 titration up to 120 mg BID / Feeling Tired or Little Energy — Several Days | 0 |
| Period 3 Day 15 / PF-06882961 titration up to 120 mg BID / Feeling Tired or Little Energy — More Than Half The Days | 0 |
| Period 3 Day 15 / PF-06882961 titration up to 120 mg BID / Feeling Tired or Little Energy — Nearly Every Day | 0 |
| Period 3 Day 15 / PF-06882961 titration up to 120 mg BID / Poor Appetite or Overeating — Not At All | 15 |
| Period 3 Day 15 / PF-06882961 titration up to 120 mg BID / Poor Appetite or Overeating — Several Days | 1 |
| Period 3 Day 15 / PF-06882961 titration up to 120 mg BID / Poor Appetite or Overeating — More Than Half The Days | 0 |
| Period 3 Day 15 / PF-06882961 titration up to 120 mg BID / Poor Appetite or Overeating — Nearly Every Day | 0 |
| Period 3 Day 15 / PF-06882961 titration up to 120 mg BID / Feeling Bad About Yourself — Not At All | 16 |
| Period 3 Day 15 / PF-06882961 titration up to 120 mg BID / Feeling Bad About Yourself — Several Days | 0 |
| Period 3 Day 15 / PF-06882961 titration up to 120 mg BID / Feeling Bad About Yourself — More Than Half The Days | 0 |
| Period 3 Day 15 / PF-06882961 titration up to 120 mg BID / Feeling Bad About Yourself — Nearly Every Day | 0 |
| Period 3 Day 15 / PF-06882961 titration up to 120 mg BID / Trouble Concentrating on Things — Not At All | 16 |
| Period 3 Day 15 / PF-06882961 titration up to 120 mg BID / Trouble Concentrating on Things — Several Days | 0 |
| Period 3 Day 15 / PF-06882961 titration up to 120 mg BID / Trouble Concentrating on Things — More Than Half The Days | 0 |
| Period 3 Day 15 / PF-06882961 titration up to 120 mg BID / Trouble Concentrating on Things — Nearly Every Day | 0 |
| Period 3 Day 15 / PF-06882961 titration up to 120 mg BID / Moving Slowly or Fidgety/Restless — Not At All | 16 |
| Period 3 Day 15 / PF-06882961 titration up to 120 mg BID / Moving Slowly or Fidgety/Restless — Several Days | 0 |
| Period 3 Day 15 / PF-06882961 titration up to 120 mg BID / Moving Slowly or Fidgety/Restless — More Than Half The Days | 0 |
| Period 3 Day 15 / PF-06882961 titration up to 120 mg BID / Moving Slowly or Fidgety/Restless — Nearly Every Day | 0 |
| Period 3 Day 15 / PF-06882961 titration up to 120 mg BID / Thoughts You Be Better Off Dead — Not At All | 16 |
| Period 3 Day 15 / PF-06882961 titration up to 120 mg BID / Thoughts You Be Better Off Dead — Several Days | 0 |
| Period 3 Day 15 / PF-06882961 titration up to 120 mg BID / Thoughts You Be Better Off Dead — More Than Half The Days | 0 |
| Period 3 Day 15 / PF-06882961 titration up to 120 mg BID / Thoughts You Be Better Off Dead — Nearly Every Day | 0 |
| Period 3 Day 23 / PF-06882961 titration up to 120 mg BID / Little Interest/Pleasure in Things — Not At All | 15 |
| Period 3 Day 23 / PF-06882961 titration up to 120 mg BID / Little Interest/Pleasure in Things — Several Days | 0 |
| Period 3 Day 23 / PF-06882961 titration up to 120 mg BID / Little Interest/Pleasure in Things — More Than Half The Days | 0 |
| Period 3 Day 23 / PF-06882961 titration up to 120 mg BID / Little Interest/Pleasure in Things — Nearly Every Day | 0 |
| Period 3 Day 23 / PF-06882961 titration up to 120 mg BID / Feeling Down Depressed or Hopeless — Not At All | 15 |
| Period 3 Day 23 / PF-06882961 titration up to 120 mg BID / Feeling Down Depressed or Hopeless — Several Days | 0 |
| Period 3 Day 23 / PF-06882961 titration up to 120 mg BID / Feeling Down Depressed or Hopeless — More Than Half The Days | 0 |
| Period 3 Day 23 / PF-06882961 titration up to 120 mg BID / Feeling Down Depressed or Hopeless — Nearly Every Day | 0 |
| Period 3 Day 23 / PF-06882961 titration up to 120 mg BID / Trouble Falling or Staying Asleep — Not At All | 15 |
| Period 3 Day 23 / PF-06882961 titration up to 120 mg BID / Trouble Falling or Staying Asleep — Several Days | 0 |
| Period 3 Day 23 / PF-06882961 titration up to 120 mg BID / Trouble Falling or Staying Asleep — More Than Half The Days | 0 |
| Period 3 Day 23 / PF-06882961 titration up to 120 mg BID / Trouble Falling or Staying Asleep — Nearly Every Day | 0 |
| Period 3 Day 23 / PF-06882961 titration up to 120 mg BID / Feeling Tired or Little Energy — Not At All | 15 |
| Period 3 Day 23 / PF-06882961 titration up to 120 mg BID / Feeling Tired or Little Energy — Several Days | 0 |
| Period 3 Day 23 / PF-06882961 titration up to 120 mg BID / Feeling Tired or Little Energy — More Than Half The Days | 0 |
| Period 3 Day 23 / PF-06882961 titration up to 120 mg BID / Feeling Tired or Little Energy — Nearly Every Day | 0 |
| Period 3 Day 23 / PF-06882961 titration up to 120 mg BID / Poor Appetite or Overeating — Not At All | 12 |
| Period 3 Day 23 / PF-06882961 titration up to 120 mg BID / Poor Appetite or Overeating — Several Days | 1 |
| Period 3 Day 23 / PF-06882961 titration up to 120 mg BID / Poor Appetite or Overeating — More Than Half The Days | 1 |
| Period 3 Day 23 / PF-06882961 titration up to 120 mg BID / Poor Appetite or Overeating — Nearly Every Day | 1 |
| Period 3 Day 23 / PF-06882961 titration up to 120 mg BID / Feeling Bad About Yourself — Not At All | 15 |
| Period 3 Day 23 / PF-06882961 titration up to 120 mg BID / Feeling Bad About Yourself — Several Days | 0 |
| Period 3 Day 23 / PF-06882961 titration up to 120 mg BID / Feeling Bad About Yourself — More Than Half The Days | 0 |
| Period 3 Day 23 / PF-06882961 titration up to 120 mg BID / Feeling Bad About Yourself — Nearly Every Day | 0 |
| Period 3 Day 23 / PF-06882961 titration up to 120 mg BID / Trouble Concentrating on Things — Not At All | 15 |
| Period 3 Day 23 / PF-06882961 titration up to 120 mg BID / Trouble Concentrating on Things — Several Days | 0 |
| Period 3 Day 23 / PF-06882961 titration up to 120 mg BID / Trouble Concentrating on Things — More Than Half The Days | 0 |
| Period 3 Day 23 / PF-06882961 titration up to 120 mg BID / Trouble Concentrating on Things — Nearly Every Day | 0 |
| Period 3 Day 23 / PF-06882961 titration up to 120 mg BID / Moving Slowly or Fidgety/Restless — Not At All | 15 |
| Period 3 Day 23 / PF-06882961 titration up to 120 mg BID / Moving Slowly or Fidgety/Restless — Several Days | 0 |
| Period 3 Day 23 / PF-06882961 titration up to 120 mg BID / Moving Slowly or Fidgety/Restless — More Than Half The Days | 0 |
| Period 3 Day 23 / PF-06882961 titration up to 120 mg BID / Moving Slowly or Fidgety/Restless — Nearly Every Day | 0 |
| Period 3 Day 23 / PF-06882961 titration up to 120 mg BID / Thoughts You Be Better Off Dead — Not At All | 15 |
| Period 3 Day 23 / PF-06882961 titration up to 120 mg BID / Thoughts You Be Better Off Dead — Several Days | 0 |
| Period 3 Day 23 / PF-06882961 titration up to 120 mg BID / Thoughts You Be Better Off Dead — More Than Half The Days | 0 |
| Period 3 Day 23 / PF-06882961 titration up to 120 mg BID / Thoughts You Be Better Off Dead — Nearly Every Day | 0 |
| Period 4 Day 1 / PF-06882961 120 mg BID + Atorvastatin 20 mg / Little Interest/Pleasure in Things — Not At All | 13 |
| Period 4 Day 1 / PF-06882961 120 mg BID + Atorvastatin 20 mg / Little Interest/Pleasure in Things — Several Days | 0 |
| Period 4 Day 1 / PF-06882961 120 mg BID + Atorvastatin 20 mg / Little Interest/Pleasure in Things — More Than Half The Days | 0 |
| Period 4 Day 1 / PF-06882961 120 mg BID + Atorvastatin 20 mg / Little Interest/Pleasure in Things — Nearly Every Day | 0 |
| Period 4 Day 1 / PF-06882961 120 mg BID + Atorvastatin 20 mg / Feeling Down Depressed or Hopeless — Not At All | 13 |
| Period 4 Day 1 / PF-06882961 120 mg BID + Atorvastatin 20 mg / Feeling Down Depressed or Hopeless — Several Days | 0 |
| Period 4 Day 1 / PF-06882961 120 mg BID + Atorvastatin 20 mg / Feeling Down Depressed or Hopeless — More Than Half The Days | 0 |
| Period 4 Day 1 / PF-06882961 120 mg BID + Atorvastatin 20 mg / Feeling Down Depressed or Hopeless — Nearly Every Day | 0 |
| Period 4 Day 1 / PF-06882961 120 mg BID + Atorvastatin 20 mg / Trouble Falling or Staying Asleep — Not At All | 13 |
| Period 4 Day 1 / PF-06882961 120 mg BID + Atorvastatin 20 mg / Trouble Falling or Staying Asleep — Several Days | 0 |
| Period 4 Day 1 / PF-06882961 120 mg BID + Atorvastatin 20 mg / Trouble Falling or Staying Asleep — More Than Half The Days | 0 |
| Period 4 Day 1 / PF-06882961 120 mg BID + Atorvastatin 20 mg / Trouble Falling or Staying Asleep — Nearly Every Day | 0 |
| Period 4 Day 1 / PF-06882961 120 mg BID + Atorvastatin 20 mg / Feeling Tired or Little Energy — Not At All | 13 |
| Period 4 Day 1 / PF-06882961 120 mg BID + Atorvastatin 20 mg / Feeling Tired or Little Energy — Several Days | 0 |
| Period 4 Day 1 / PF-06882961 120 mg BID + Atorvastatin 20 mg / Feeling Tired or Little Energy — More Than Half The Days | 0 |
| Period 4 Day 1 / PF-06882961 120 mg BID + Atorvastatin 20 mg / Feeling Tired or Little Energy — Nearly Every Day | 0 |
| Period 4 Day 1 / PF-06882961 120 mg BID + Atorvastatin 20 mg / Poor Appetite or Overeating — Not At All | 10 |
| Period 4 Day 1 / PF-06882961 120 mg BID + Atorvastatin 20 mg / Poor Appetite or Overeating — Several Days | 2 |
| Period 4 Day 1 / PF-06882961 120 mg BID + Atorvastatin 20 mg / Poor Appetite or Overeating — More Than Half The Days | 0 |
| Period 4 Day 1 / PF-06882961 120 mg BID + Atorvastatin 20 mg / Poor Appetite or Overeating — Nearly Every Day | 1 |
| Period 4 Day 1 / PF-06882961 120 mg BID + Atorvastatin 20 mg / Feeling Bad About Yourself — Not At All | 13 |
| Period 4 Day 1 / PF-06882961 120 mg BID + Atorvastatin 20 mg / Feeling Bad About Yourself — Several Days | 0 |
| Period 4 Day 1 / PF-06882961 120 mg BID + Atorvastatin 20 mg / Feeling Bad About Yourself — More Than Half The Days | 0 |
| Period 4 Day 1 / PF-06882961 120 mg BID + Atorvastatin 20 mg / Feeling Bad About Yourself — Nearly Every Day | 0 |
| Period 4 Day 1 / PF-06882961 120 mg BID + Atorvastatin 20 mg / Trouble Concentrating on Things — Not At All | 13 |
| Period 4 Day 1 / PF-06882961 120 mg BID + Atorvastatin 20 mg / Trouble Concentrating on Things — Several Days | 0 |
| Period 4 Day 1 / PF-06882961 120 mg BID + Atorvastatin 20 mg / Trouble Concentrating on Things — More Than Half The Days | 0 |
| Period 4 Day 1 / PF-06882961 120 mg BID + Atorvastatin 20 mg / Trouble Concentrating on Things — Nearly Every Day | 0 |
| Period 4 Day 1 / PF-06882961 120 mg BID + Atorvastatin 20 mg / Moving Slowly or Fidgety/Restless — Not At All | 13 |
| Period 4 Day 1 / PF-06882961 120 mg BID + Atorvastatin 20 mg / Moving Slowly or Fidgety/Restless — Several Days | 0 |
| Period 4 Day 1 / PF-06882961 120 mg BID + Atorvastatin 20 mg / Moving Slowly or Fidgety/Restless — More Than Half The Days | 0 |
| Period 4 Day 1 / PF-06882961 120 mg BID + Atorvastatin 20 mg / Moving Slowly or Fidgety/Restless — Nearly Every Day | 0 |
| Period 4 Day 1 / PF-06882961 120 mg BID + Atorvastatin 20 mg / Thoughts You Be Better Off Dead — Not At All | 13 |
| Period 4 Day 1 / PF-06882961 120 mg BID + Atorvastatin 20 mg / Thoughts You Be Better Off Dead — Several Days | 0 |
| Period 4 Day 1 / PF-06882961 120 mg BID + Atorvastatin 20 mg / Thoughts You Be Better Off Dead — More Than Half The Days | 0 |
| Period 4 Day 1 / PF-06882961 120 mg BID + Atorvastatin 20 mg / Thoughts You Be Better Off Dead — Nearly Every Day | 0 |
| Period 6 Day 1 / PF-06882961 titration up to 200 mg BID / Little Interest/Pleasure in Things — Not At All | 13 |
| Period 6 Day 1 / PF-06882961 titration up to 200 mg BID / Little Interest/Pleasure in Things — Several Days | 0 |
| Period 6 Day 1 / PF-06882961 titration up to 200 mg BID / Little Interest/Pleasure in Things — More Than Half The Days | 0 |
| Period 6 Day 1 / PF-06882961 titration up to 200 mg BID / Little Interest/Pleasure in Things — Nearly Every Day | 0 |
| Period 6 Day 1 / PF-06882961 titration up to 200 mg BID / Feeling Down Depressed or Hopeless — Not At All | 13 |
| Period 6 Day 1 / PF-06882961 titration up to 200 mg BID / Feeling Down Depressed or Hopeless — Several Days | 0 |
| Period 6 Day 1 / PF-06882961 titration up to 200 mg BID / Feeling Down Depressed or Hopeless — More Than Half The Days | 0 |
| Period 6 Day 1 / PF-06882961 titration up to 200 mg BID / Feeling Down Depressed or Hopeless — Nearly Every Day | 0 |
| Period 6 Day 1 / PF-06882961 titration up to 200 mg BID / Trouble Falling or Staying Asleep — Not At All | 12 |
| Period 6 Day 1 / PF-06882961 titration up to 200 mg BID / Trouble Falling or Staying Asleep — Several Days | 0 |
| Period 6 Day 1 / PF-06882961 titration up to 200 mg BID / Trouble Falling or Staying Asleep — More Than Half The Days | 1 |
| Period 6 Day 1 / PF-06882961 titration up to 200 mg BID / Trouble Falling or Staying Asleep — Nearly Every Day | 0 |
| Period 6 Day 1 / PF-06882961 titration up to 200 mg BID / Feeling Tired or Little Energy — Not At All | 12 |
| Period 6 Day 1 / PF-06882961 titration up to 200 mg BID / Feeling Tired or Little Energy — Several Days | 1 |
| Period 6 Day 1 / PF-06882961 titration up to 200 mg BID / Feeling Tired or Little Energy — More Than Half The Days | 0 |
| Period 6 Day 1 / PF-06882961 titration up to 200 mg BID / Feeling Tired or Little Energy — Nearly Every Day | 0 |
| Period 6 Day 1 / PF-06882961 titration up to 200 mg BID / Poor Appetite or Overeating — Not At All | 8 |
| Period 6 Day 1 / PF-06882961 titration up to 200 mg BID / Poor Appetite or Overeating — Several Days | 2 |
| Period 6 Day 1 / PF-06882961 titration up to 200 mg BID / Poor Appetite or Overeating — More Than Half The Days | 1 |
| Period 6 Day 1 / PF-06882961 titration up to 200 mg BID / Poor Appetite or Overeating — Nearly Every Day | 2 |
| Period 6 Day 1 / PF-06882961 titration up to 200 mg BID / Feeling Bad About Yourself — Not At All | 13 |
| Period 6 Day 1 / PF-06882961 titration up to 200 mg BID / Feeling Bad About Yourself — Several Days | 0 |
| Period 6 Day 1 / PF-06882961 titration up to 200 mg BID / Feeling Bad About Yourself — More Than Half The Days | 0 |
| Period 6 Day 1 / PF-06882961 titration up to 200 mg BID / Feeling Bad About Yourself — Nearly Every Day | 0 |
| Period 6 Day 1 / PF-06882961 titration up to 200 mg BID / Trouble Concentrating on Things — Not At All | 13 |
| Period 6 Day 1 / PF-06882961 titration up to 200 mg BID / Trouble Concentrating on Things — Several Days | 0 |
| Period 6 Day 1 / PF-06882961 titration up to 200 mg BID / Trouble Concentrating on Things — More Than Half The Days | 0 |
| Period 6 Day 1 / PF-06882961 titration up to 200 mg BID / Trouble Concentrating on Things — Nearly Every Day | 0 |
| Period 6 Day 1 / PF-06882961 titration up to 200 mg BID / Moving Slowly or Fidgety/Restless — Not At All | 13 |
| Period 6 Day 1 / PF-06882961 titration up to 200 mg BID / Moving Slowly or Fidgety/Restless — Several Days | 0 |
| Period 6 Day 1 / PF-06882961 titration up to 200 mg BID / Moving Slowly or Fidgety/Restless — More Than Half The Days | 0 |
| Period 6 Day 1 / PF-06882961 titration up to 200 mg BID / Moving Slowly or Fidgety/Restless — Nearly Every Day | 0 |
| Period 6 Day 1 / PF-06882961 titration up to 200 mg BID / Thoughts You Be Better Off Dead — Not At All | 13 |
| Period 6 Day 1 / PF-06882961 titration up to 200 mg BID / Thoughts You Be Better Off Dead — Several Days | 0 |
| Period 6 Day 1 / PF-06882961 titration up to 200 mg BID / Thoughts You Be Better Off Dead — More Than Half The Days | 0 |
| Period 6 Day 1 / PF-06882961 titration up to 200 mg BID / Thoughts You Be Better Off Dead — Nearly Every Day | 0 |
| Period 6 Day 9 / PF-06882961 titration up to 200 mg BID / Little Interest/Pleasure in Things — Not At All | 11 |
| Period 6 Day 9 / PF-06882961 titration up to 200 mg BID / Little Interest/Pleasure in Things — Several Days | 2 |
| Period 6 Day 9 / PF-06882961 titration up to 200 mg BID / Little Interest/Pleasure in Things — More Than Half The Days | 0 |
| Period 6 Day 9 / PF-06882961 titration up to 200 mg BID / Little Interest/Pleasure in Things — Nearly Every Day | 0 |
| Period 6 Day 9 / PF-06882961 titration up to 200 mg BID / Feeling Down Depressed or Hopeless — Not At All | 13 |
| Period 6 Day 9 / PF-06882961 titration up to 200 mg BID / Feeling Down Depressed or Hopeless — Several Days | 0 |
| Period 6 Day 9 / PF-06882961 titration up to 200 mg BID / Feeling Down Depressed or Hopeless — More Than Half The Days | 0 |
| Period 6 Day 9 / PF-06882961 titration up to 200 mg BID / Feeling Down Depressed or Hopeless — Nearly Every Day | 0 |
| Period 6 Day 9 / PF-06882961 titration up to 200 mg BID / Trouble Falling or Staying Asleep — Not At All | 11 |
| Period 6 Day 9 / PF-06882961 titration up to 200 mg BID / Trouble Falling or Staying Asleep — Several Days | 1 |
| Period 6 Day 9 / PF-06882961 titration up to 200 mg BID / Trouble Falling or Staying Asleep — More Than Half The Days | 0 |
| Period 6 Day 9 / PF-06882961 titration up to 200 mg BID / Trouble Falling or Staying Asleep — Nearly Every Day | 1 |
| Period 6 Day 9 / PF-06882961 titration up to 200 mg BID /Feeling Tired or Little Energy — Not At All | 10 |
| Period 6 Day 9 / PF-06882961 titration up to 200 mg BID /Feeling Tired or Little Energy — Several Days | 2 |
| Period 6 Day 9 / PF-06882961 titration up to 200 mg BID /Feeling Tired or Little Energy — More Than Half The Days | 1 |
| Period 6 Day 9 / PF-06882961 titration up to 200 mg BID /Feeling Tired or Little Energy — Nearly Every Day | 0 |
| Period 6 Day 9 / PF-06882961 titration up to 200 mg BID / Poor Appetite or Overeating — Not At All | 7 |
| Period 6 Day 9 / PF-06882961 titration up to 200 mg BID / Poor Appetite or Overeating — Several Days | 2 |
| Period 6 Day 9 / PF-06882961 titration up to 200 mg BID / Poor Appetite or Overeating — More Than Half The Days | 1 |
| Period 6 Day 9 / PF-06882961 titration up to 200 mg BID / Poor Appetite or Overeating — Nearly Every Day | 3 |
| Period 6 Day 9 / PF-06882961 titration up to 200 mg BID / Feeling Bad About Yourself — Not At All | 13 |
| Period 6 Day 9 / PF-06882961 titration up to 200 mg BID / Feeling Bad About Yourself — Several Days | 0 |
| Period 6 Day 9 / PF-06882961 titration up to 200 mg BID / Feeling Bad About Yourself — More Than Half The Days | 0 |
| Period 6 Day 9 / PF-06882961 titration up to 200 mg BID / Feeling Bad About Yourself — Nearly Every Day | 0 |
| Period 6 Day 9 / PF-06882961 titration up to 200 mg BID / Trouble Concentrating on Things — Not At All | 13 |
| Period 6 Day 9 / PF-06882961 titration up to 200 mg BID / Trouble Concentrating on Things — Several Days | 0 |
| Period 6 Day 9 / PF-06882961 titration up to 200 mg BID / Trouble Concentrating on Things — More Than Half The Days | 0 |
| Period 6 Day 9 / PF-06882961 titration up to 200 mg BID / Trouble Concentrating on Things — Nearly Every Day | 0 |
| Period 6 Day 9 / PF-06882961 titration up to 200 mg BID / Moving Slowly or Fidgety/Restless — Not At All | 13 |
| Period 6 Day 9 / PF-06882961 titration up to 200 mg BID / Moving Slowly or Fidgety/Restless — Several Days | 0 |
| Period 6 Day 9 / PF-06882961 titration up to 200 mg BID / Moving Slowly or Fidgety/Restless — More Than Half The Days | 0 |
| Period 6 Day 9 / PF-06882961 titration up to 200 mg BID / Moving Slowly or Fidgety/Restless — Nearly Every Day | 0 |
| Period 6 Day 9 / PF-06882961 titration up to 200 mg BID / Thoughts You Be Better Off Dead — Not At All | 13 |
| Period 6 Day 9 / PF-06882961 titration up to 200 mg BID / Thoughts You Be Better Off Dead — Several Days | 0 |
| Period 6 Day 9 / PF-06882961 titration up to 200 mg BID / Thoughts You Be Better Off Dead — More Than Half The Days | 0 |
| Period 6 Day 9 / PF-06882961 titration up to 200 mg BID / Thoughts You Be Better Off Dead — Nearly Every Day | 0 |
| Period 6 Day 19 / PF-06882961 titration up to 200 mg BID / Little Interest/Pleasure in Things — Not At All | 5 |
| Period 6 Day 19 / PF-06882961 titration up to 200 mg BID / Little Interest/Pleasure in Things — Several Days | 1 |
| Period 6 Day 19 / PF-06882961 titration up to 200 mg BID / Little Interest/Pleasure in Things — More Than Half The Days | 0 |
| Period 6 Day 19 / PF-06882961 titration up to 200 mg BID / Little Interest/Pleasure in Things — Nearly Every Day | 0 |
| Period 6 Day 19 / PF-06882961 titration up to 200 mg BID / Feeling Down Depressed or Hopeless — Not At All | 6 |
| Period 6 Day 19 / PF-06882961 titration up to 200 mg BID / Feeling Down Depressed or Hopeless — Several Days | 0 |
| Period 6 Day 19 / PF-06882961 titration up to 200 mg BID / Feeling Down Depressed or Hopeless — More Than Half The Days | 0 |
| Period 6 Day 19 / PF-06882961 titration up to 200 mg BID / Feeling Down Depressed or Hopeless — Nearly Every Day | 0 |
| Period 6 Day 19 / PF-06882961 titration up to 200 mg BID / Trouble Falling or Staying Asleep — Not At All | 5 |
| Period 6 Day 19 / PF-06882961 titration up to 200 mg BID / Trouble Falling or Staying Asleep — Several Days | 1 |
| Period 6 Day 19 / PF-06882961 titration up to 200 mg BID / Trouble Falling or Staying Asleep — More Than Half The Days | 0 |
| Period 6 Day 19 / PF-06882961 titration up to 200 mg BID / Trouble Falling or Staying Asleep — Nearly Every Day | 0 |
| Period 6 Day 19 / PF-06882961 titration up to 200 mg BID / Feeling Tired or Little Energy — Not At All | 5 |
| Period 6 Day 19 / PF-06882961 titration up to 200 mg BID / Feeling Tired or Little Energy — Several Days | 0 |
| Period 6 Day 19 / PF-06882961 titration up to 200 mg BID / Feeling Tired or Little Energy — More Than Half The Days | 1 |
| Period 6 Day 19 / PF-06882961 titration up to 200 mg BID / Feeling Tired or Little Energy — Nearly Every Day | 0 |
| Period 6 Day 19 / PF-06882961 titration up to 200 mg BID / Poor Appetite or Overeating — Not At All | 5 |
| Period 6 Day 19 / PF-06882961 titration up to 200 mg BID / Poor Appetite or Overeating — Several Days | 0 |
| Period 6 Day 19 / PF-06882961 titration up to 200 mg BID / Poor Appetite or Overeating — More Than Half The Days | 1 |
| Period 6 Day 19 / PF-06882961 titration up to 200 mg BID / Poor Appetite or Overeating — Nearly Every Day | 0 |
| Period 6 Day 19 / PF-06882961 titration up to 200 mg BID / Feeling Bad About Yourself — Not At All | 6 |
| Period 6 Day 19 / PF-06882961 titration up to 200 mg BID / Feeling Bad About Yourself — Several Days | 0 |
| Period 6 Day 19 / PF-06882961 titration up to 200 mg BID / Feeling Bad About Yourself — More Than Half The Days | 0 |
| Period 6 Day 19 / PF-06882961 titration up to 200 mg BID / Feeling Bad About Yourself — Nearly Every Day | 0 |
| Period 6 Day 19 / PF-06882961 titration up to 200 mg BID / Trouble Concentrating on Things — Not At All | 5 |
| Period 6 Day 19 / PF-06882961 titration up to 200 mg BID / Trouble Concentrating on Things — Several Days | 1 |
| Period 6 Day 19 / PF-06882961 titration up to 200 mg BID / Trouble Concentrating on Things — More Than Half The Days | 0 |
| Period 6 Day 19 / PF-06882961 titration up to 200 mg BID / Trouble Concentrating on Things — Nearly Every Day | 0 |
| Period 6 Day 19 / PF-06882961 titration up to 200 mg BID / Moving Slowly or Fidgety/Restless — Not At All | 5 |
| Period 6 Day 19 / PF-06882961 titration up to 200 mg BID / Moving Slowly or Fidgety/Restless — Several Days | 1 |
| Period 6 Day 19 / PF-06882961 titration up to 200 mg BID / Moving Slowly or Fidgety/Restless — More Than Half The Days | 0 |
| Period 6 Day 19 / PF-06882961 titration up to 200 mg BID / Moving Slowly or Fidgety/Restless — Nearly Every Day | 0 |
| Period 6 Day 19 / PF-06882961 titration up to 200 mg BID / Thoughts You Be Better Off Dead — Not At All | 6 |
| Period 6 Day 19 / PF-06882961 titration up to 200 mg BID / Thoughts You Be Better Off Dead — Several Days | 0 |
| Period 6 Day 19 / PF-06882961 titration up to 200 mg BID / Thoughts You Be Better Off Dead — More Than Half The Days | 0 |
| Period 6 Day 19 / PF-06882961 titration up to 200 mg BID / Thoughts You Be Better Off Dead — Nearly Every Day | 0 |
| Period 8 Day 1 / PF-06882961 200 mg BID + Midazolam 5 mg / Little Interest/Pleasure in Things — Not At All | 5 |
| Period 8 Day 1 / PF-06882961 200 mg BID + Midazolam 5 mg / Little Interest/Pleasure in Things — Several Days | 1 |
| Period 8 Day 1 / PF-06882961 200 mg BID + Midazolam 5 mg / Little Interest/Pleasure in Things — More Than Half The Days | 0 |
| Period 8 Day 1 / PF-06882961 200 mg BID + Midazolam 5 mg / Little Interest/Pleasure in Things — Nearly Every Day | 0 |
| Period 8 Day 1 / PF-06882961 200 mg BID + Midazolam 5 mg / Feeling Down Depressed or Hopeless — Not At All | 5 |
| Period 8 Day 1 / PF-06882961 200 mg BID + Midazolam 5 mg / Feeling Down Depressed or Hopeless — Several Days | 1 |
| Period 8 Day 1 / PF-06882961 200 mg BID + Midazolam 5 mg / Feeling Down Depressed or Hopeless — More Than Half The Days | 0 |
| Period 8 Day 1 / PF-06882961 200 mg BID + Midazolam 5 mg / Feeling Down Depressed or Hopeless — Nearly Every Day | 0 |
| Period 8 Day 1 / PF-06882961 200 mg BID + Midazolam 5 mg / Trouble Falling or Staying Asleep — Not At All | 5 |
| Period 8 Day 1 / PF-06882961 200 mg BID + Midazolam 5 mg / Trouble Falling or Staying Asleep — Several Days | 1 |
| Period 8 Day 1 / PF-06882961 200 mg BID + Midazolam 5 mg / Trouble Falling or Staying Asleep — More Than Half The Days | 0 |
| Period 8 Day 1 / PF-06882961 200 mg BID + Midazolam 5 mg / Trouble Falling or Staying Asleep — Nearly Every Day | 0 |
| Period 8 Day 1 / PF-06882961 200 mg BID + Midazolam 5 mg / Feeling Tired or Little Energy — Not At All | 5 |
| Period 8 Day 1 / PF-06882961 200 mg BID + Midazolam 5 mg / Feeling Tired or Little Energy — Several Days | 1 |
| Period 8 Day 1 / PF-06882961 200 mg BID + Midazolam 5 mg / Feeling Tired or Little Energy — More Than Half The Days | 0 |
| Period 8 Day 1 / PF-06882961 200 mg BID + Midazolam 5 mg / Feeling Tired or Little Energy — Nearly Every Day | 0 |
| Period 8 Day 1 / PF-06882961 200 mg BID + Midazolam 5 mg / Poor Appetite or Overeating — Not At All | 5 |
| Period 8 Day 1 / PF-06882961 200 mg BID + Midazolam 5 mg / Poor Appetite or Overeating — Several Days | 0 |
| Period 8 Day 1 / PF-06882961 200 mg BID + Midazolam 5 mg / Poor Appetite or Overeating — More Than Half The Days | 1 |
| Period 8 Day 1 / PF-06882961 200 mg BID + Midazolam 5 mg / Poor Appetite or Overeating — Nearly Every Day | 0 |
| Period 8 Day 1 / PF-06882961 200 mg BID + Midazolam 5 mg / Feeling Bad About Yourself — Not At All | 6 |
| Period 8 Day 1 / PF-06882961 200 mg BID + Midazolam 5 mg / Feeling Bad About Yourself — Several Days | 0 |
| Period 8 Day 1 / PF-06882961 200 mg BID + Midazolam 5 mg / Feeling Bad About Yourself — More Than Half The Days | 0 |
| Period 8 Day 1 / PF-06882961 200 mg BID + Midazolam 5 mg / Feeling Bad About Yourself — Nearly Every Day | 0 |
| Period 8 Day 1 / PF-06882961 200 mg BID + Midazolam 5 mg / Trouble Concentrating on Things — Not At All | 5 |
| Period 8 Day 1 / PF-06882961 200 mg BID + Midazolam 5 mg / Trouble Concentrating on Things — Several Days | 1 |
| Period 8 Day 1 / PF-06882961 200 mg BID + Midazolam 5 mg / Trouble Concentrating on Things — More Than Half The Days | 0 |
| Period 8 Day 1 / PF-06882961 200 mg BID + Midazolam 5 mg / Trouble Concentrating on Things — Nearly Every Day | 0 |
| Period 8 Day 1 / PF-06882961 200 mg BID + Midazolam 5 mg / Moving Slowly or Fidgety/Restless — Not At All | 5 |
| Period 8 Day 1 / PF-06882961 200 mg BID + Midazolam 5 mg / Moving Slowly or Fidgety/Restless — Several Days | 1 |
| Period 8 Day 1 / PF-06882961 200 mg BID + Midazolam 5 mg / Moving Slowly or Fidgety/Restless — More Than Half The Days | 0 |
| Period 8 Day 1 / PF-06882961 200 mg BID + Midazolam 5 mg / Moving Slowly or Fidgety/Restless — Nearly Every Day | 0 |
| Period 8 Day 1 / PF-06882961 200 mg BID + Midazolam 5 mg / Thoughts You Be Better Off Dead — Not At All | 6 |
| Period 8 Day 1 / PF-06882961 200 mg BID + Midazolam 5 mg / Thoughts You Be Better Off Dead — Several Days | 0 |
| Period 8 Day 1 / PF-06882961 200 mg BID + Midazolam 5 mg / Thoughts You Be Better Off Dead — More Than Half The Days | 0 |
| Period 8 Day 1 / PF-06882961 200 mg BID + Midazolam 5 mg / Thoughts You Be Better Off Dead — Nearly Every Day | 0 |
| Follow Up — Not At All | 14 |
| Follow Up — Several Days | 1 |
| Follow Up — More Than Half The Days | 0 |
| Follow Up — Nearly Every Day | 0 |
The PHQ-9 is a 9 item self-report scale for the assessment of depressive symptoms. The questions included "little interest/pleasure in things", "feeling down depressed or hopeless", "trouble falling or staying asleep", "feeling tired or little energy", "poor appetite or overeating", "feeling bad about yourself", "trouble concentrating on things", "moving slowly or fidgety/restless" and "thoughts you be better off dead". Each item was scored on scale of "not at all", "several days", "more than half the days" to "nearly every day". Total score range: 0-27 (each item with scale from 0 \[not at all\] to 3 \[nearly every day\]. Higher score=greater severity).
| Participants | All Participants in Part B |
|---|---|
| Period 1 Day -1 / 0.15 mg LE & 0.03 mg EE / Little Interest/Pleasure in Things — Not At All | 17 |
| Period 1 Day -1 / 0.15 mg LE & 0.03 mg EE / Little Interest/Pleasure in Things — Several Days | 0 |
| Period 1 Day -1 / 0.15 mg LE & 0.03 mg EE / Little Interest/Pleasure in Things — More Than Half The Days | 0 |
| Period 1 Day -1 / 0.15 mg LE & 0.03 mg EE / Little Interest/Pleasure in Things — Nearly Every Day | 0 |
| Period 1 Day -1 / 0.15 mg LE & 0.03 mg EE / Feeling Down Depressed or Hopeless — Not At All | 16 |
| Period 1 Day -1 / 0.15 mg LE & 0.03 mg EE / Feeling Down Depressed or Hopeless — Several Days | 1 |
| Period 1 Day -1 / 0.15 mg LE & 0.03 mg EE / Feeling Down Depressed or Hopeless — More Than Half The Days | 0 |
| Period 1 Day -1 / 0.15 mg LE & 0.03 mg EE / Feeling Down Depressed or Hopeless — Nearly Every Day | 0 |
| Period 1 Day -1 / 0.15 mg LE & 0.03 mg EE / Trouble Falling or Staying Asleep — Not At All | 17 |
| Period 1 Day -1 / 0.15 mg LE & 0.03 mg EE / Trouble Falling or Staying Asleep — Several Days | 0 |
| Period 1 Day -1 / 0.15 mg LE & 0.03 mg EE / Trouble Falling or Staying Asleep — More Than Half The Days | 0 |
| Period 1 Day -1 / 0.15 mg LE & 0.03 mg EE / Trouble Falling or Staying Asleep — Nearly Every Day | 0 |
| Period 1 Day -1 / 0.15 mg LE & 0.03 mg EE / Feeling Tired or Little Energy — Not At All | 16 |
| Period 1 Day -1 / 0.15 mg LE & 0.03 mg EE / Feeling Tired or Little Energy — Several Days | 1 |
| Period 1 Day -1 / 0.15 mg LE & 0.03 mg EE / Feeling Tired or Little Energy — More Than Half The Days | 0 |
| Period 1 Day -1 / 0.15 mg LE & 0.03 mg EE / Feeling Tired or Little Energy — Nearly Every Day | 0 |
| Period 1 Day -1 / 0.15 mg LE & 0.03 mg EE / Poor Appetite or Overeating — Not At All | 16 |
| Period 1 Day -1 / 0.15 mg LE & 0.03 mg EE / Poor Appetite or Overeating — Several Days | 1 |
| Period 1 Day -1 / 0.15 mg LE & 0.03 mg EE / Poor Appetite or Overeating — More Than Half The Days | 0 |
| Period 1 Day -1 / 0.15 mg LE & 0.03 mg EE / Poor Appetite or Overeating — Nearly Every Day | 0 |
| Period 1 Day -1 / 0.15 mg LE & 0.03 mg EE / Feeling Bad About Yourself — Not At All | 16 |
| Period 1 Day -1 / 0.15 mg LE & 0.03 mg EE / Feeling Bad About Yourself — Several Days | 1 |
| Period 1 Day -1 / 0.15 mg LE & 0.03 mg EE / Feeling Bad About Yourself — More Than Half The Days | 0 |
| Period 1 Day -1 / 0.15 mg LE & 0.03 mg EE / Feeling Bad About Yourself — Nearly Every Day | 0 |
| Period 1 Day -1 / 0.15 mg LE & 0.03 mg EE / Trouble Concentrating on Things — Not At All | 17 |
| Period 1 Day -1 / 0.15 mg LE & 0.03 mg EE / Trouble Concentrating on Things — Several Days | 0 |
| Period 1 Day -1 / 0.15 mg LE & 0.03 mg EE / Trouble Concentrating on Things — More Than Half The Days | 0 |
| Period 1 Day -1 / 0.15 mg LE & 0.03 mg EE / Trouble Concentrating on Things — Nearly Every Day | 0 |
| Period 1 Day -1 / 0.15 mg LE & 0.03 mg EE / Moving Slowly or Fidgety/Restless — Not At All | 17 |
| Period 1 Day -1 / 0.15 mg LE & 0.03 mg EE / Moving Slowly or Fidgety/Restless — Several Days | 0 |
| Period 1 Day -1 / 0.15 mg LE & 0.03 mg EE / Moving Slowly or Fidgety/Restless — More Than Half The Days | 0 |
| Period 1 Day -1 / 0.15 mg LE & 0.03 mg EE / Moving Slowly or Fidgety/Restless — Nearly Every Day | 0 |
| Period 1 Day -1 / 0.15 mg LE & 0.03 mg EE / Thoughts You Be Better Off Dead — Not At All | 17 |
| Period 1 Day -1 / 0.15 mg LE & 0.03 mg EE / Thoughts You Be Better Off Dead — Several Days | 0 |
| Period 1 Day -1 / 0.15 mg LE & 0.03 mg EE / Thoughts You Be Better Off Dead — More Than Half The Days | 0 |
| Period 1 Day -1 / 0.15 mg LE & 0.03 mg EE / Thoughts You Be Better Off Dead — Nearly Every Day | 0 |
| Period 2 Day 1 / PF-06882961 titration up to 120 mg BID / Little Interest/Pleasure in Things — Not At All | 16 |
| Period 2 Day 1 / PF-06882961 titration up to 120 mg BID / Little Interest/Pleasure in Things — Several Days | 0 |
| Period 2 Day 1 / PF-06882961 titration up to 120 mg BID / Little Interest/Pleasure in Things — More Than Half The Days | 0 |
| Period 2 Day 1 / PF-06882961 titration up to 120 mg BID / Little Interest/Pleasure in Things — Nearly Every Day | 0 |
| Period 2 Day 1 / PF-06882961 titration up to 120 mg BID / Feeling Down Depressed or Hopeless — Not At All | 16 |
| Period 2 Day 1 / PF-06882961 titration up to 120 mg BID / Feeling Down Depressed or Hopeless — Several Days | 0 |
| Period 2 Day 1 / PF-06882961 titration up to 120 mg BID / Feeling Down Depressed or Hopeless — More Than Half The Days | 0 |
| Period 2 Day 1 / PF-06882961 titration up to 120 mg BID / Feeling Down Depressed or Hopeless — Nearly Every Day | 0 |
| Period 2 Day 1 / PF-06882961 titration up to 120 mg BID / Trouble Falling or Staying Asleep — Not At All | 16 |
| Period 2 Day 1 / PF-06882961 titration up to 120 mg BID / Trouble Falling or Staying Asleep — Several Days | 0 |
| Period 2 Day 1 / PF-06882961 titration up to 120 mg BID / Trouble Falling or Staying Asleep — More Than Half The Days | 0 |
| Period 2 Day 1 / PF-06882961 titration up to 120 mg BID / Trouble Falling or Staying Asleep — Nearly Every Day | 0 |
| Period 2 Day 1 / PF-06882961 titration up to 120 mg BID / Feeling Tired or Little Energy — Not At All | 15 |
| Period 2 Day 1 / PF-06882961 titration up to 120 mg BID / Feeling Tired or Little Energy — Several Days | 1 |
| Period 2 Day 1 / PF-06882961 titration up to 120 mg BID / Feeling Tired or Little Energy — More Than Half The Days | 0 |
| Period 2 Day 1 / PF-06882961 titration up to 120 mg BID / Feeling Tired or Little Energy — Nearly Every Day | 0 |
| Period 2 Day 1 / PF-06882961 titration up to 120 mg BID / Poor Appetite or Overeating — Not At All | 15 |
| Period 2 Day 1 / PF-06882961 titration up to 120 mg BID / Poor Appetite or Overeating — Several Days | 1 |
| Period 2 Day 1 / PF-06882961 titration up to 120 mg BID / Poor Appetite or Overeating — More Than Half The Days | 0 |
| Period 2 Day 1 / PF-06882961 titration up to 120 mg BID / Poor Appetite or Overeating — Nearly Every Day | 0 |
| Period 2 Day 1 / PF-06882961 titration up to 120 mg BID / Feeling Bad About Yourself — Not At All | 15 |
| Period 2 Day 1 / PF-06882961 titration up to 120 mg BID / Feeling Bad About Yourself — Several Days | 1 |
| Period 2 Day 1 / PF-06882961 titration up to 120 mg BID / Feeling Bad About Yourself — More Than Half The Days | 0 |
| Period 2 Day 1 / PF-06882961 titration up to 120 mg BID / Feeling Bad About Yourself — Nearly Every Day | 0 |
| Period 2 Day 1 / PF-06882961 titration up to 120 mg BID / Trouble Concentrating on Things — Not At All | 15 |
| Period 2 Day 1 / PF-06882961 titration up to 120 mg BID / Trouble Concentrating on Things — Several Days | 1 |
| Period 2 Day 1 / PF-06882961 titration up to 120 mg BID / Trouble Concentrating on Things — More Than Half The Days | 0 |
| Period 2 Day 1 / PF-06882961 titration up to 120 mg BID / Trouble Concentrating on Things — Nearly Every Day | 0 |
| Period 2 Day 1 / PF-06882961 titration up to 120 mg BID / Moving Slowly or Fidgety/Restless — Not At All | 16 |
| Period 2 Day 1 / PF-06882961 titration up to 120 mg BID / Moving Slowly or Fidgety/Restless — Several Days | 0 |
| Period 2 Day 1 / PF-06882961 titration up to 120 mg BID / Moving Slowly or Fidgety/Restless — More Than Half The Days | 0 |
| Period 2 Day 1 / PF-06882961 titration up to 120 mg BID / Moving Slowly or Fidgety/Restless — Nearly Every Day | 0 |
| Period 2 Day 1 / PF-06882961 titration up to 120 mg BID / Thoughts You Be Better Off Dead — Not At All | 16 |
| Period 2 Day 1 / PF-06882961 titration up to 120 mg BID / Thoughts You Be Better Off Dead — Several Days | 0 |
| Period 2 Day 1 / PF-06882961 titration up to 120 mg BID / Thoughts You Be Better Off Dead — More Than Half The Days | 0 |
| Period 2 Day 1 / PF-06882961 titration up to 120 mg BID / Thoughts You Be Better Off Dead — Nearly Every Day | 0 |
| Period 2 Day 8 / PF-06882961 titration up to 120 mg BID / Little Interest/Pleasure in Things — Not At All | 16 |
| Period 2 Day 8 / PF-06882961 titration up to 120 mg BID / Little Interest/Pleasure in Things — Several Days | 0 |
| Period 2 Day 8 / PF-06882961 titration up to 120 mg BID / Little Interest/Pleasure in Things — More Than Half The Days | 0 |
| Period 2 Day 8 / PF-06882961 titration up to 120 mg BID / Little Interest/Pleasure in Things — Nearly Every Day | 0 |
| Period 2 Day 8 / PF-06882961 titration up to 120 mg BID / Feeling Down Depressed or Hopeless — Not At All | 16 |
| Period 2 Day 8 / PF-06882961 titration up to 120 mg BID / Feeling Down Depressed or Hopeless — Several Days | 0 |
| Period 2 Day 8 / PF-06882961 titration up to 120 mg BID / Feeling Down Depressed or Hopeless — More Than Half The Days | 0 |
| Period 2 Day 8 / PF-06882961 titration up to 120 mg BID / Feeling Down Depressed or Hopeless — Nearly Every Day | 0 |
| Period 2 Day 8 / PF-06882961 titration up to 120 mg BID / Trouble Falling or Staying Asleep — Not At All | 16 |
| Period 2 Day 8 / PF-06882961 titration up to 120 mg BID / Trouble Falling or Staying Asleep — Several Days | 0 |
| Period 2 Day 8 / PF-06882961 titration up to 120 mg BID / Trouble Falling or Staying Asleep — More Than Half The Days | 0 |
| Period 2 Day 8 / PF-06882961 titration up to 120 mg BID / Trouble Falling or Staying Asleep — Nearly Every Day | 0 |
| Period 2 Day 8 / PF-06882961 titration up to 120 mg BID / Feeling Tired or Little Energy — Not At All | 15 |
| Period 2 Day 8 / PF-06882961 titration up to 120 mg BID / Feeling Tired or Little Energy — Several Days | 1 |
| Period 2 Day 8 / PF-06882961 titration up to 120 mg BID / Feeling Tired or Little Energy — More Than Half The Days | 0 |
| Period 2 Day 8 / PF-06882961 titration up to 120 mg BID / Feeling Tired or Little Energy — Nearly Every Day | 0 |
| Period 2 Day 8 / PF-06882961 titration up to 120 mg BID / Poor Appetite or Overeating — Not At All | 15 |
| Period 2 Day 8 / PF-06882961 titration up to 120 mg BID / Poor Appetite or Overeating — Several Days | 1 |
| Period 2 Day 8 / PF-06882961 titration up to 120 mg BID / Poor Appetite or Overeating — More Than Half The Days | 0 |
| Period 2 Day 8 / PF-06882961 titration up to 120 mg BID / Poor Appetite or Overeating — Nearly Every Day | 0 |
| Period 2 Day 8 / PF-06882961 titration up to 120 mg BID / Feeling Bad About Yourself — Not At All | 16 |
| Period 2 Day 8 / PF-06882961 titration up to 120 mg BID / Feeling Bad About Yourself — Several Days | 0 |
| Period 2 Day 8 / PF-06882961 titration up to 120 mg BID / Feeling Bad About Yourself — More Than Half The Days | 0 |
| Period 2 Day 8 / PF-06882961 titration up to 120 mg BID / Feeling Bad About Yourself — Nearly Every Day | 0 |
| Period 2 Day 8 / PF-06882961 titration up to 120 mg BID / Trouble Concentrating on Things — Not At All | 16 |
| Period 2 Day 8 / PF-06882961 titration up to 120 mg BID / Trouble Concentrating on Things — Several Days | 0 |
| Period 2 Day 8 / PF-06882961 titration up to 120 mg BID / Trouble Concentrating on Things — More Than Half The Days | 0 |
| Period 2 Day 8 / PF-06882961 titration up to 120 mg BID / Trouble Concentrating on Things — Nearly Every Day | 0 |
| Period 2 Day 8 / PF-06882961 titration up to 120 mg BID / Moving Slowly or Fidgety/Restless — Not At All | 16 |
| Period 2 Day 8 / PF-06882961 titration up to 120 mg BID / Moving Slowly or Fidgety/Restless — Several Days | 0 |
| Period 2 Day 8 / PF-06882961 titration up to 120 mg BID / Moving Slowly or Fidgety/Restless — More Than Half The Days | 0 |
| Period 2 Day 8 / PF-06882961 titration up to 120 mg BID / Moving Slowly or Fidgety/Restless — Nearly Every Day | 0 |
| Period 2 Day 8 / PF-06882961 titration up to 120 mg BID / Thoughts You Be Better Off Dead — Not At All | 16 |
| Period 2 Day 8 / PF-06882961 titration up to 120 mg BID / Thoughts You Be Better Off Dead — Several Days | 0 |
| Period 2 Day 8 / PF-06882961 titration up to 120 mg BID / Thoughts You Be Better Off Dead — More Than Half The Days | 0 |
| Period 2 Day 8 / PF-06882961 titration up to 120 mg BID / Thoughts You Be Better Off Dead — Nearly Every Day | 0 |
| Period 2 Day 15 / PF-06882961 titration up to 120 mg BID / Little Interest/Pleasure in Things — Not At All | 15 |
| Period 2 Day 15 / PF-06882961 titration up to 120 mg BID / Little Interest/Pleasure in Things — Several Days | 1 |
| Period 2 Day 15 / PF-06882961 titration up to 120 mg BID / Little Interest/Pleasure in Things — More Than Half The Days | 0 |
| Period 2 Day 15 / PF-06882961 titration up to 120 mg BID / Little Interest/Pleasure in Things — Nearly Every Day | 0 |
| Period 2 Day 15 / PF-06882961 titration up to 120 mg BID / Feeling Down Depressed or Hopeless — Not At All | 16 |
| Period 2 Day 15 / PF-06882961 titration up to 120 mg BID / Feeling Down Depressed or Hopeless — Several Days | 0 |
| Period 2 Day 15 / PF-06882961 titration up to 120 mg BID / Feeling Down Depressed or Hopeless — More Than Half The Days | 0 |
| Period 2 Day 15 / PF-06882961 titration up to 120 mg BID / Feeling Down Depressed or Hopeless — Nearly Every Day | 0 |
| Period 2 Day 15 / PF-06882961 titration up to 120 mg BID / Trouble Falling or Staying Asleep — Not At All | 16 |
| Period 2 Day 15 / PF-06882961 titration up to 120 mg BID / Trouble Falling or Staying Asleep — Several Days | 0 |
| Period 2 Day 15 / PF-06882961 titration up to 120 mg BID / Trouble Falling or Staying Asleep — More Than Half The Days | 0 |
| Period 2 Day 15 / PF-06882961 titration up to 120 mg BID / Trouble Falling or Staying Asleep — Nearly Every Day | 0 |
| Period 2 Day 15 / PF-06882961 titration up to 120 mg BID / Feeling Tired or Little Energy — Not At All | 15 |
| Period 2 Day 15 / PF-06882961 titration up to 120 mg BID / Feeling Tired or Little Energy — Several Days | 1 |
| Period 2 Day 15 / PF-06882961 titration up to 120 mg BID / Feeling Tired or Little Energy — More Than Half The Days | 0 |
| Period 2 Day 15 / PF-06882961 titration up to 120 mg BID / Feeling Tired or Little Energy — Nearly Every Day | 0 |
| Period 2 Day 15 / PF-06882961 titration up to 120 mg BID / Poor Appetite or Overeating — Not At All | 13 |
| Period 2 Day 15 / PF-06882961 titration up to 120 mg BID / Poor Appetite or Overeating — Several Days | 1 |
| Period 2 Day 15 / PF-06882961 titration up to 120 mg BID / Poor Appetite or Overeating — More Than Half The Days | 2 |
| Period 2 Day 15 / PF-06882961 titration up to 120 mg BID / Poor Appetite or Overeating — Nearly Every Day | 0 |
| Period 2 Day 15 / PF-06882961 titration up to 120 mg BID / Feeling Bad About Yourself — Not At All | 16 |
| Period 2 Day 15 / PF-06882961 titration up to 120 mg BID / Feeling Bad About Yourself — Several Days | 0 |
| Period 2 Day 15 / PF-06882961 titration up to 120 mg BID / Feeling Bad About Yourself — More Than Half The Days | 0 |
| Period 2 Day 15 / PF-06882961 titration up to 120 mg BID / Feeling Bad About Yourself — Nearly Every Day | 0 |
| Period 2 Day 15 / PF-06882961 titration up to 120 mg BID / Trouble Concentrating on Things — Not At All | 16 |
| Period 2 Day 15 / PF-06882961 titration up to 120 mg BID / Trouble Concentrating on Things — Several Days | 0 |
| Period 2 Day 15 / PF-06882961 titration up to 120 mg BID / Trouble Concentrating on Things — More Than Half The Days | 0 |
| Period 2 Day 15 / PF-06882961 titration up to 120 mg BID / Trouble Concentrating on Things — Nearly Every Day | 0 |
| Period 2 Day 15 / PF-06882961 titration up to 120 mg BID / Moving Slowly or Fidgety/Restless — Not At All | 16 |
| Period 2 Day 15 / PF-06882961 titration up to 120 mg BID / Moving Slowly or Fidgety/Restless — Several Days | 0 |
| Period 2 Day 15 / PF-06882961 titration up to 120 mg BID / Moving Slowly or Fidgety/Restless — More Than Half The Days | 0 |
| Period 2 Day 15 / PF-06882961 titration up to 120 mg BID / Moving Slowly or Fidgety/Restless — Nearly Every Day | 0 |
| Period 2 Day 15 / PF-06882961 titration up to 120 mg BID / Thoughts You Be Better Off Dead — Not At All | 16 |
| Period 2 Day 15 / PF-06882961 titration up to 120 mg BID / Thoughts You Be Better Off Dead — Several Days | 0 |
| Period 2 Day 15 / PF-06882961 titration up to 120 mg BID / Thoughts You Be Better Off Dead — More Than Half The Days | 0 |
| Period 2 Day 15 / PF-06882961 titration up to 120 mg BID / Thoughts You Be Better Off Dead — Nearly Every Day | 0 |
| Period 2 Day 22 / PF-06882961 titration up to 120 mg BID / Little Interest/Pleasure in Things — Not At All | 15 |
| Period 2 Day 22 / PF-06882961 titration up to 120 mg BID / Little Interest/Pleasure in Things — Several Days | 1 |
| Period 2 Day 22 / PF-06882961 titration up to 120 mg BID / Little Interest/Pleasure in Things — More Than Half The Days | 0 |
| Period 2 Day 22 / PF-06882961 titration up to 120 mg BID / Little Interest/Pleasure in Things — Nearly Every Day | 0 |
| Period 2 Day 22 / PF-06882961 titration up to 120 mg BID / Feeling Down Depressed or Hopeless — Not At All | 16 |
| Period 2 Day 22 / PF-06882961 titration up to 120 mg BID / Feeling Down Depressed or Hopeless — Several Days | 0 |
| Period 2 Day 22 / PF-06882961 titration up to 120 mg BID / Feeling Down Depressed or Hopeless — More Than Half The Days | 0 |
| Period 2 Day 22 / PF-06882961 titration up to 120 mg BID / Feeling Down Depressed or Hopeless — Nearly Every Day | 0 |
| Period 2 Day 22 / PF-06882961 titration up to 120 mg BID / Trouble Falling or Staying Asleep — Not At All | 16 |
| Period 2 Day 22 / PF-06882961 titration up to 120 mg BID / Trouble Falling or Staying Asleep — Several Days | 0 |
| Period 2 Day 22 / PF-06882961 titration up to 120 mg BID / Trouble Falling or Staying Asleep — More Than Half The Days | 0 |
| Period 2 Day 22 / PF-06882961 titration up to 120 mg BID / Trouble Falling or Staying Asleep — Nearly Every Day | 0 |
| Period 2 Day 22 / PF-06882961 titration up to 120 mg BID / Feeling Tired or Little Energy — Not At All | 15 |
| Period 2 Day 22 / PF-06882961 titration up to 120 mg BID / Feeling Tired or Little Energy — Several Days | 1 |
| Period 2 Day 22 / PF-06882961 titration up to 120 mg BID / Feeling Tired or Little Energy — More Than Half The Days | 0 |
| Period 2 Day 22 / PF-06882961 titration up to 120 mg BID / Feeling Tired or Little Energy — Nearly Every Day | 0 |
| Period 2 Day 22 / PF-06882961 titration up to 120 mg BID / Poor Appetite or Overeating — Not At All | 13 |
| Period 2 Day 22 / PF-06882961 titration up to 120 mg BID / Poor Appetite or Overeating — Several Days | 3 |
| Period 2 Day 22 / PF-06882961 titration up to 120 mg BID / Poor Appetite or Overeating — More Than Half The Days | 0 |
| Period 2 Day 22 / PF-06882961 titration up to 120 mg BID / Poor Appetite or Overeating — Nearly Every Day | 0 |
| Period 2 Day 22 / PF-06882961 titration up to 120 mg BID / Feeling Bad About Yourself — Not At All | 16 |
| Period 2 Day 22 / PF-06882961 titration up to 120 mg BID / Feeling Bad About Yourself — Several Days | 0 |
| Period 2 Day 22 / PF-06882961 titration up to 120 mg BID / Feeling Bad About Yourself — More Than Half The Days | 0 |
| Period 2 Day 22 / PF-06882961 titration up to 120 mg BID / Feeling Bad About Yourself — Nearly Every Day | 0 |
| Period 2 Day 22 / PF-06882961 titration up to 120 mg BID / Trouble Concentrating on Things — Not At All | 16 |
| Period 2 Day 22 / PF-06882961 titration up to 120 mg BID / Trouble Concentrating on Things — Several Days | 0 |
| Period 2 Day 22 / PF-06882961 titration up to 120 mg BID / Trouble Concentrating on Things — More Than Half The Days | 0 |
| Period 2 Day 22 / PF-06882961 titration up to 120 mg BID / Trouble Concentrating on Things — Nearly Every Day | 0 |
| Period 2 Day 22 / PF-06882961 titration up to 120 mg BID / Moving Slowly or Fidgety/Restless — Not At All | 16 |
| Period 2 Day 22 / PF-06882961 titration up to 120 mg BID / Moving Slowly or Fidgety/Restless — Several Days | 0 |
| Period 2 Day 22 / PF-06882961 titration up to 120 mg BID / Moving Slowly or Fidgety/Restless — More Than Half The Days | 0 |
| Period 2 Day 22 / PF-06882961 titration up to 120 mg BID / Moving Slowly or Fidgety/Restless — Nearly Every Day | 0 |
| Period 2 Day 22 / PF-06882961 titration up to 120 mg BID / Thoughts You Be Better Off Dead — Not At All | 16 |
| Period 2 Day 22 / PF-06882961 titration up to 120 mg BID / Thoughts You Be Better Off Dead — Several Days | 0 |
| Period 2 Day 22 / PF-06882961 titration up to 120 mg BID / Thoughts You Be Better Off Dead — More Than Half The Days | 0 |
| Period 2 Day 22 / PF-06882961 titration up to 120 mg BID / Thoughts You Be Better Off Dead — Nearly Every Day | 0 |
| Period 3 Day 1 / PF-06882961 120mg BID + 0.15mg LE & 0.03mg EE/Little Interest/Pleasure in Things — Not At All | 13 |
| Period 3 Day 1 / PF-06882961 120mg BID + 0.15mg LE & 0.03mg EE/Little Interest/Pleasure in Things — Several Days | 1 |
| Period 3 Day 1 / PF-06882961 120mg BID + 0.15mg LE & 0.03mg EE/Little Interest/Pleasure in Things — More Than Half The Days | 0 |
| Period 3 Day 1 / PF-06882961 120mg BID + 0.15mg LE & 0.03mg EE/Little Interest/Pleasure in Things — Nearly Every Day | 1 |
| Period 3 Day 1/PF-06882961 120mg BID + 0.15mg LE & 0.03mg EE/Feeling Down Depressed or Hopeless — Not At All | 15 |
| Period 3 Day 1/PF-06882961 120mg BID + 0.15mg LE & 0.03mg EE/Feeling Down Depressed or Hopeless — Several Days | 0 |
| Period 3 Day 1/PF-06882961 120mg BID + 0.15mg LE & 0.03mg EE/Feeling Down Depressed or Hopeless — More Than Half The Days | 0 |
| Period 3 Day 1/PF-06882961 120mg BID + 0.15mg LE & 0.03mg EE/Feeling Down Depressed or Hopeless — Nearly Every Day | 0 |
| Period 3 Day 1/PF-06882961 120mg BID + 0.15mg LE & 0.03mg EE/Trouble Falling or Staying Asleep — Not At All | 14 |
| Period 3 Day 1/PF-06882961 120mg BID + 0.15mg LE & 0.03mg EE/Trouble Falling or Staying Asleep — Several Days | 0 |
| Period 3 Day 1/PF-06882961 120mg BID + 0.15mg LE & 0.03mg EE/Trouble Falling or Staying Asleep — More Than Half The Days | 1 |
| Period 3 Day 1/PF-06882961 120mg BID + 0.15mg LE & 0.03mg EE/Trouble Falling or Staying Asleep — Nearly Every Day | 0 |
| Period 3 Day 1 / PF-06882961 120mg BID + 0.15mg LE & 0.03mg EE/Feeling Tired or Little Energy — Not At All | 13 |
| Period 3 Day 1 / PF-06882961 120mg BID + 0.15mg LE & 0.03mg EE/Feeling Tired or Little Energy — Several Days | 1 |
| Period 3 Day 1 / PF-06882961 120mg BID + 0.15mg LE & 0.03mg EE/Feeling Tired or Little Energy — More Than Half The Days | 0 |
| Period 3 Day 1 / PF-06882961 120mg BID + 0.15mg LE & 0.03mg EE/Feeling Tired or Little Energy — Nearly Every Day | 1 |
| Period 3 Day 1 / PF-06882961 120 mg BID + 0.15 mg LE & 0.03 mg EE / Poor Appetite or Overeating — Not At All | 10 |
| Period 3 Day 1 / PF-06882961 120 mg BID + 0.15 mg LE & 0.03 mg EE / Poor Appetite or Overeating — Several Days | 0 |
| Period 3 Day 1 / PF-06882961 120 mg BID + 0.15 mg LE & 0.03 mg EE / Poor Appetite or Overeating — More Than Half The Days | 3 |
| Period 3 Day 1 / PF-06882961 120 mg BID + 0.15 mg LE & 0.03 mg EE / Poor Appetite or Overeating — Nearly Every Day | 2 |
| Period 3 Day 1 / PF-06882961 120 mg BID + 0.15 mg LE & 0.03 mg EE / Feeling Bad About Yourself — Not At All | 15 |
| Period 3 Day 1 / PF-06882961 120 mg BID + 0.15 mg LE & 0.03 mg EE / Feeling Bad About Yourself — Several Days | 0 |
| Period 3 Day 1 / PF-06882961 120 mg BID + 0.15 mg LE & 0.03 mg EE / Feeling Bad About Yourself — More Than Half The Days | 0 |
| Period 3 Day 1 / PF-06882961 120 mg BID + 0.15 mg LE & 0.03 mg EE / Feeling Bad About Yourself — Nearly Every Day | 0 |
| Period 3 Day 1/PF-06882961 120mg BID + 0.15mg LE & 0.03mg EE/ Trouble Concentrating on Things — Not At All | 14 |
| Period 3 Day 1/PF-06882961 120mg BID + 0.15mg LE & 0.03mg EE/ Trouble Concentrating on Things — Several Days | 1 |
| Period 3 Day 1/PF-06882961 120mg BID + 0.15mg LE & 0.03mg EE/ Trouble Concentrating on Things — More Than Half The Days | 0 |
| Period 3 Day 1/PF-06882961 120mg BID + 0.15mg LE & 0.03mg EE/ Trouble Concentrating on Things — Nearly Every Day | 0 |
| Period 3 Day 1/PF-06882961 120mg BID + 0.15mg LE & 0.03mg EE/Moving Slowly or Fidgety/Restless — Not At All | 14 |
| Period 3 Day 1/PF-06882961 120mg BID + 0.15mg LE & 0.03mg EE/Moving Slowly or Fidgety/Restless — Several Days | 0 |
| Period 3 Day 1/PF-06882961 120mg BID + 0.15mg LE & 0.03mg EE/Moving Slowly or Fidgety/Restless — More Than Half The Days | 1 |
| Period 3 Day 1/PF-06882961 120mg BID + 0.15mg LE & 0.03mg EE/Moving Slowly or Fidgety/Restless — Nearly Every Day | 0 |
| Period 3 Day 1 / PF-06882961 120 mg BID + 0.15 mg LE & 0.03 mg EE / Thoughts You Be Better Off Dead — Not At All | 15 |
| Period 3 Day 1 / PF-06882961 120 mg BID + 0.15 mg LE & 0.03 mg EE / Thoughts You Be Better Off Dead — Several Days | 0 |
| Period 3 Day 1 / PF-06882961 120 mg BID + 0.15 mg LE & 0.03 mg EE / Thoughts You Be Better Off Dead — More Than Half The Days | 0 |
| Period 3 Day 1 / PF-06882961 120 mg BID + 0.15 mg LE & 0.03 mg EE / Thoughts You Be Better Off Dead — Nearly Every Day | 0 |
| Period 4 Day 1 / PF-06882961 titration up to 200 mg BID / Little Interest/Pleasure in Things — Not At All | 11 |
| Period 4 Day 1 / PF-06882961 titration up to 200 mg BID / Little Interest/Pleasure in Things — Several Days | 1 |
| Period 4 Day 1 / PF-06882961 titration up to 200 mg BID / Little Interest/Pleasure in Things — More Than Half The Days | 0 |
| Period 4 Day 1 / PF-06882961 titration up to 200 mg BID / Little Interest/Pleasure in Things — Nearly Every Day | 0 |
| Period 4 Day 1 / PF-06882961 titration up to 200 mg BID / Feeling Down Depressed or Hopeless — Not At All | 12 |
| Period 4 Day 1 / PF-06882961 titration up to 200 mg BID / Feeling Down Depressed or Hopeless — Several Days | 0 |
| Period 4 Day 1 / PF-06882961 titration up to 200 mg BID / Feeling Down Depressed or Hopeless — More Than Half The Days | 0 |
| Period 4 Day 1 / PF-06882961 titration up to 200 mg BID / Feeling Down Depressed or Hopeless — Nearly Every Day | 0 |
| Period 4 Day 1 / PF-06882961 titration up to 200 mg BID / Trouble Falling or Staying Asleep — Not At All | 12 |
| Period 4 Day 1 / PF-06882961 titration up to 200 mg BID / Trouble Falling or Staying Asleep — Several Days | 0 |
| Period 4 Day 1 / PF-06882961 titration up to 200 mg BID / Trouble Falling or Staying Asleep — More Than Half The Days | 0 |
| Period 4 Day 1 / PF-06882961 titration up to 200 mg BID / Trouble Falling or Staying Asleep — Nearly Every Day | 0 |
| Period 4 Day 1 / PF-06882961 titration up to 200 mg BID / Feeling Tired or Little Energy — Not At All | 10 |
| Period 4 Day 1 / PF-06882961 titration up to 200 mg BID / Feeling Tired or Little Energy — Several Days | 2 |
| Period 4 Day 1 / PF-06882961 titration up to 200 mg BID / Feeling Tired or Little Energy — More Than Half The Days | 0 |
| Period 4 Day 1 / PF-06882961 titration up to 200 mg BID / Feeling Tired or Little Energy — Nearly Every Day | 0 |
| Period 4 Day 1 / PF-06882961 titration up to 200 mg BID / Poor Appetite or Overeating — Not At All | 9 |
| Period 4 Day 1 / PF-06882961 titration up to 200 mg BID / Poor Appetite or Overeating — Several Days | 0 |
| Period 4 Day 1 / PF-06882961 titration up to 200 mg BID / Poor Appetite or Overeating — More Than Half The Days | 1 |
| Period 4 Day 1 / PF-06882961 titration up to 200 mg BID / Poor Appetite or Overeating — Nearly Every Day | 2 |
| Period 4 Day 1 / PF-06882961 titration up to 200 mg BID / Feeling Bad About Yourself — Not At All | 12 |
| Period 4 Day 1 / PF-06882961 titration up to 200 mg BID / Feeling Bad About Yourself — Several Days | 0 |
| Period 4 Day 1 / PF-06882961 titration up to 200 mg BID / Feeling Bad About Yourself — More Than Half The Days | 0 |
| Period 4 Day 1 / PF-06882961 titration up to 200 mg BID / Feeling Bad About Yourself — Nearly Every Day | 0 |
| Period 4 Day 1 / PF-06882961 titration up to 200 mg BID / Trouble Concentrating on Things — Not At All | 12 |
| Period 4 Day 1 / PF-06882961 titration up to 200 mg BID / Trouble Concentrating on Things — Several Days | 0 |
| Period 4 Day 1 / PF-06882961 titration up to 200 mg BID / Trouble Concentrating on Things — More Than Half The Days | 0 |
| Period 4 Day 1 / PF-06882961 titration up to 200 mg BID / Trouble Concentrating on Things — Nearly Every Day | 0 |
| Period 4 Day 1 / PF-06882961 titration up to 200 mg BID / Moving Slowly or Fidgety/Restless — Not At All | 12 |
| Period 4 Day 1 / PF-06882961 titration up to 200 mg BID / Moving Slowly or Fidgety/Restless — Several Days | 0 |
| Period 4 Day 1 / PF-06882961 titration up to 200 mg BID / Moving Slowly or Fidgety/Restless — More Than Half The Days | 0 |
| Period 4 Day 1 / PF-06882961 titration up to 200 mg BID / Moving Slowly or Fidgety/Restless — Nearly Every Day | 0 |
| Period 4 Day 1 / PF-06882961 titration up to 200 mg BID / Thoughts You Be Better Off Dead — Not At All | 12 |
| Period 4 Day 1 / PF-06882961 titration up to 200 mg BID / Thoughts You Be Better Off Dead — Several Days | 0 |
| Period 4 Day 1 / PF-06882961 titration up to 200 mg BID / Thoughts You Be Better Off Dead — More Than Half The Days | 0 |
| Period 4 Day 1 / PF-06882961 titration up to 200 mg BID / Thoughts You Be Better Off Dead — Nearly Every Day | 0 |
| Period 4 Day 9 / PF-06882961 titration up to 200 mg BID / Little Interest/Pleasure in Things — Not At All | 11 |
| Period 4 Day 9 / PF-06882961 titration up to 200 mg BID / Little Interest/Pleasure in Things — Several Days | 0 |
| Period 4 Day 9 / PF-06882961 titration up to 200 mg BID / Little Interest/Pleasure in Things — More Than Half The Days | 0 |
| Period 4 Day 9 / PF-06882961 titration up to 200 mg BID / Little Interest/Pleasure in Things — Nearly Every Day | 0 |
| Period 4 Day 9 / PF-06882961 titration up to 200 mg BID / Feeling Down Depressed or Hopeless — Not At All | 11 |
| Period 4 Day 9 / PF-06882961 titration up to 200 mg BID / Feeling Down Depressed or Hopeless — Several Days | 0 |
| Period 4 Day 9 / PF-06882961 titration up to 200 mg BID / Feeling Down Depressed or Hopeless — More Than Half The Days | 0 |
| Period 4 Day 9 / PF-06882961 titration up to 200 mg BID / Feeling Down Depressed or Hopeless — Nearly Every Day | 0 |
| Period 4 Day 9 / PF-06882961 titration up to 200 mg BID / Trouble Falling or Staying Asleep — Not At All | 10 |
| Period 4 Day 9 / PF-06882961 titration up to 200 mg BID / Trouble Falling or Staying Asleep — Several Days | 1 |
| Period 4 Day 9 / PF-06882961 titration up to 200 mg BID / Trouble Falling or Staying Asleep — More Than Half The Days | 0 |
| Period 4 Day 9 / PF-06882961 titration up to 200 mg BID / Trouble Falling or Staying Asleep — Nearly Every Day | 0 |
| Period 4 Day 9 / PF-06882961 titration up to 200 mg BID / Feeling Tired or Little Energy — Not At All | 10 |
| Period 4 Day 9 / PF-06882961 titration up to 200 mg BID / Feeling Tired or Little Energy — Several Days | 1 |
| Period 4 Day 9 / PF-06882961 titration up to 200 mg BID / Feeling Tired or Little Energy — More Than Half The Days | 0 |
| Period 4 Day 9 / PF-06882961 titration up to 200 mg BID / Feeling Tired or Little Energy — Nearly Every Day | 0 |
| Period 4 Day 9 / PF-06882961 titration up to 200 mg BID / Poor Appetite or Overeating — Not At All | 8 |
| Period 4 Day 9 / PF-06882961 titration up to 200 mg BID / Poor Appetite or Overeating — Several Days | 1 |
| Period 4 Day 9 / PF-06882961 titration up to 200 mg BID / Poor Appetite or Overeating — More Than Half The Days | 1 |
| Period 4 Day 9 / PF-06882961 titration up to 200 mg BID / Poor Appetite or Overeating — Nearly Every Day | 1 |
| Period 4 Day 9 / PF-06882961 titration up to 200 mg BID / Feeling Bad About Yourself — Not At All | 11 |
| Period 4 Day 9 / PF-06882961 titration up to 200 mg BID / Feeling Bad About Yourself — Several Days | 0 |
| Period 4 Day 9 / PF-06882961 titration up to 200 mg BID / Feeling Bad About Yourself — More Than Half The Days | 0 |
| Period 4 Day 9 / PF-06882961 titration up to 200 mg BID / Feeling Bad About Yourself — Nearly Every Day | 0 |
| Period 4 Day 9 / PF-06882961 titration up to 200 mg BID / Trouble Concentrating on Things — Not At All | 10 |
| Period 4 Day 9 / PF-06882961 titration up to 200 mg BID / Trouble Concentrating on Things — Several Days | 1 |
| Period 4 Day 9 / PF-06882961 titration up to 200 mg BID / Trouble Concentrating on Things — More Than Half The Days | 0 |
| Period 4 Day 9 / PF-06882961 titration up to 200 mg BID / Trouble Concentrating on Things — Nearly Every Day | 0 |
| Period 4 Day 9 / PF-06882961 titration up to 200 mg BID / Moving Slowly or Fidgety/Restless — Not At All | 10 |
| Period 4 Day 9 / PF-06882961 titration up to 200 mg BID / Moving Slowly or Fidgety/Restless — Several Days | 1 |
| Period 4 Day 9 / PF-06882961 titration up to 200 mg BID / Moving Slowly or Fidgety/Restless — More Than Half The Days | 0 |
| Period 4 Day 9 / PF-06882961 titration up to 200 mg BID / Moving Slowly or Fidgety/Restless — Nearly Every Day | 0 |
| Period 4 Day 9 / PF-06882961 titration up to 200 mg BID / Thoughts You Be Better Off Dead — Not At All | 11 |
| Period 4 Day 9 / PF-06882961 titration up to 200 mg BID / Thoughts You Be Better Off Dead — Several Days | 0 |
| Period 4 Day 9 / PF-06882961 titration up to 200 mg BID / Thoughts You Be Better Off Dead — More Than Half The Days | 0 |
| Period 4 Day 9 / PF-06882961 titration up to 200 mg BID / Thoughts You Be Better Off Dead — Nearly Every Day | 0 |
| Period 4 Day 19 / PF-06882961 titration up to 200 mg BID /Little Interest/Pleasure in Things — Not At All | 9 |
| Period 4 Day 19 / PF-06882961 titration up to 200 mg BID /Little Interest/Pleasure in Things — Several Days | 0 |
| Period 4 Day 19 / PF-06882961 titration up to 200 mg BID /Little Interest/Pleasure in Things — More Than Half The Days | 0 |
| Period 4 Day 19 / PF-06882961 titration up to 200 mg BID /Little Interest/Pleasure in Things — Nearly Every Day | 0 |
| Period 4 Day 19 / PF-06882961 titration up to 200 mg BID /Feeling Down Depressed or Hopeless — Not At All | 9 |
| Period 4 Day 19 / PF-06882961 titration up to 200 mg BID /Feeling Down Depressed or Hopeless — Several Days | 0 |
| Period 4 Day 19 / PF-06882961 titration up to 200 mg BID /Feeling Down Depressed or Hopeless — More Than Half The Days | 0 |
| Period 4 Day 19 / PF-06882961 titration up to 200 mg BID /Feeling Down Depressed or Hopeless — Nearly Every Day | 0 |
| Period 4 Day 19 / PF-06882961 titration up to 200 mg BID /Trouble Falling or Staying Asleep — Not At All | 8 |
| Period 4 Day 19 / PF-06882961 titration up to 200 mg BID /Trouble Falling or Staying Asleep — Several Days | 1 |
| Period 4 Day 19 / PF-06882961 titration up to 200 mg BID /Trouble Falling or Staying Asleep — More Than Half The Days | 0 |
| Period 4 Day 19 / PF-06882961 titration up to 200 mg BID /Trouble Falling or Staying Asleep — Nearly Every Day | 0 |
| Period 4 Day 19 / PF-06882961 titration up to 200 mg BID /Feeling Tired or Little Energy — Not At All | 8 |
| Period 4 Day 19 / PF-06882961 titration up to 200 mg BID /Feeling Tired or Little Energy — Several Days | 0 |
| Period 4 Day 19 / PF-06882961 titration up to 200 mg BID /Feeling Tired or Little Energy — More Than Half The Days | 0 |
| Period 4 Day 19 / PF-06882961 titration up to 200 mg BID /Feeling Tired or Little Energy — Nearly Every Day | 1 |
| Period 4 Day 19 / PF-06882961 titration up to 200 mg BID /Poor Appetite or Overeating — Not At All | 7 |
| Period 4 Day 19 / PF-06882961 titration up to 200 mg BID /Poor Appetite or Overeating — Several Days | 0 |
| Period 4 Day 19 / PF-06882961 titration up to 200 mg BID /Poor Appetite or Overeating — More Than Half The Days | 1 |
| Period 4 Day 19 / PF-06882961 titration up to 200 mg BID /Poor Appetite or Overeating — Nearly Every Day | 1 |
| Period 4 Day 19 / PF-06882961 titration up to 200 mg BID /Feeling Bad About Yourself — Not At All | 9 |
| Period 4 Day 19 / PF-06882961 titration up to 200 mg BID /Feeling Bad About Yourself — Several Days | 0 |
| Period 4 Day 19 / PF-06882961 titration up to 200 mg BID /Feeling Bad About Yourself — More Than Half The Days | 0 |
| Period 4 Day 19 / PF-06882961 titration up to 200 mg BID /Feeling Bad About Yourself — Nearly Every Day | 0 |
| Period 4 Day 19 / PF-06882961 titration up to 200 mg BID /Trouble Concentrating on Things — Not At All | 8 |
| Period 4 Day 19 / PF-06882961 titration up to 200 mg BID /Trouble Concentrating on Things — Several Days | 0 |
| Period 4 Day 19 / PF-06882961 titration up to 200 mg BID /Trouble Concentrating on Things — More Than Half The Days | 1 |
| Period 4 Day 19 / PF-06882961 titration up to 200 mg BID /Trouble Concentrating on Things — Nearly Every Day | 0 |
| Period 4 Day 19 / PF-06882961 titration up to 200 mg BID /Moving Slowly or Fidgety/Restless — Not At All | 8 |
| Period 4 Day 19 / PF-06882961 titration up to 200 mg BID /Moving Slowly or Fidgety/Restless — Several Days | 0 |
| Period 4 Day 19 / PF-06882961 titration up to 200 mg BID /Moving Slowly or Fidgety/Restless — More Than Half The Days | 0 |
| Period 4 Day 19 / PF-06882961 titration up to 200 mg BID /Moving Slowly or Fidgety/Restless — Nearly Every Day | 1 |
| Period 4 Day 19 / PF-06882961 titration up to 200 mg BID /Thoughts You Be Better Off Dead — Not At All | 9 |
| Period 4 Day 19 / PF-06882961 titration up to 200 mg BID /Thoughts You Be Better Off Dead — Several Days | 0 |
| Period 4 Day 19 / PF-06882961 titration up to 200 mg BID /Thoughts You Be Better Off Dead — More Than Half The Days | 0 |
| Period 4 Day 19 / PF-06882961 titration up to 200 mg BID /Thoughts You Be Better Off Dead — Nearly Every Day | 0 |
| Period 5 Day 6/PF-06882961 200mg BID+0.15mg LE & 0.03mg EE/Little Interest/Pleasure in Things — Not At All | 9 |
| Period 5 Day 6/PF-06882961 200mg BID+0.15mg LE & 0.03mg EE/Little Interest/Pleasure in Things — Several Days | 0 |
| Period 5 Day 6/PF-06882961 200mg BID+0.15mg LE & 0.03mg EE/Little Interest/Pleasure in Things — More Than Half The Days | 0 |
| Period 5 Day 6/PF-06882961 200mg BID+0.15mg LE & 0.03mg EE/Little Interest/Pleasure in Things — Nearly Every Day | 0 |
| Period 5 Day 6/PF-06882961 200mg BID+0.15mg LE & 0.03mg EE/Feeling Down Depressed or Hopeless — Not At All | 9 |
| Period 5 Day 6/PF-06882961 200mg BID+0.15mg LE & 0.03mg EE/Feeling Down Depressed or Hopeless — Several Days | 0 |
| Period 5 Day 6/PF-06882961 200mg BID+0.15mg LE & 0.03mg EE/Feeling Down Depressed or Hopeless — More Than Half The Days | 0 |
| Period 5 Day 6/PF-06882961 200mg BID+0.15mg LE & 0.03mg EE/Feeling Down Depressed or Hopeless — Nearly Every Day | 0 |
| Period 5 Day 6/PF-06882961 200mg BID+0.15mg LE & 0.03mg EE/Trouble Falling or Staying Asleep — Not At All | 8 |
| Period 5 Day 6/PF-06882961 200mg BID+0.15mg LE & 0.03mg EE/Trouble Falling or Staying Asleep — Several Days | 0 |
| Period 5 Day 6/PF-06882961 200mg BID+0.15mg LE & 0.03mg EE/Trouble Falling or Staying Asleep — More Than Half The Days | 0 |
| Period 5 Day 6/PF-06882961 200mg BID+0.15mg LE & 0.03mg EE/Trouble Falling or Staying Asleep — Nearly Every Day | 1 |
| Period 5 Day 6/PF-06882961 200mg BID+0.15mg LE & 0.03mg EE/Feeling Tired or Little Energy — Not At All | 8 |
| Period 5 Day 6/PF-06882961 200mg BID+0.15mg LE & 0.03mg EE/Feeling Tired or Little Energy — Several Days | 0 |
| Period 5 Day 6/PF-06882961 200mg BID+0.15mg LE & 0.03mg EE/Feeling Tired or Little Energy — More Than Half The Days | 0 |
| Period 5 Day 6/PF-06882961 200mg BID+0.15mg LE & 0.03mg EE/Feeling Tired or Little Energy — Nearly Every Day | 1 |
| Period 5 Day 6/PF-06882961 200mg BID+0.15mg LE & 0.03mg EE/Poor Appetite or Overeating — Not At All | 7 |
| Period 5 Day 6/PF-06882961 200mg BID+0.15mg LE & 0.03mg EE/Poor Appetite or Overeating — Several Days | 0 |
| Period 5 Day 6/PF-06882961 200mg BID+0.15mg LE & 0.03mg EE/Poor Appetite or Overeating — More Than Half The Days | 1 |
| Period 5 Day 6/PF-06882961 200mg BID+0.15mg LE & 0.03mg EE/Poor Appetite or Overeating — Nearly Every Day | 1 |
| Period 5 Day 6/PF-06882961 200mg BID+0.15mg LE & 0.03mg EE/Feeling Bad About Yourself — Not At All | 9 |
| Period 5 Day 6/PF-06882961 200mg BID+0.15mg LE & 0.03mg EE/Feeling Bad About Yourself — Several Days | 0 |
| Period 5 Day 6/PF-06882961 200mg BID+0.15mg LE & 0.03mg EE/Feeling Bad About Yourself — More Than Half The Days | 0 |
| Period 5 Day 6/PF-06882961 200mg BID+0.15mg LE & 0.03mg EE/Feeling Bad About Yourself — Nearly Every Day | 0 |
| Period 5 Day 6/PF-06882961 200mg BID+0.15mg LE & 0.03mg EE/Trouble Concentrating on Things — Not At All | 8 |
| Period 5 Day 6/PF-06882961 200mg BID+0.15mg LE & 0.03mg EE/Trouble Concentrating on Things — Several Days | 0 |
| Period 5 Day 6/PF-06882961 200mg BID+0.15mg LE & 0.03mg EE/Trouble Concentrating on Things — More Than Half The Days | 0 |
| Period 5 Day 6/PF-06882961 200mg BID+0.15mg LE & 0.03mg EE/Trouble Concentrating on Things — Nearly Every Day | 1 |
| Period 5 Day 6/PF-06882961 200mg BID+0.15mg LE & 0.03mg EE/Moving Slowly or Fidgety/Restless — Not At All | 8 |
| Period 5 Day 6/PF-06882961 200mg BID+0.15mg LE & 0.03mg EE/Moving Slowly or Fidgety/Restless — Several Days | 0 |
| Period 5 Day 6/PF-06882961 200mg BID+0.15mg LE & 0.03mg EE/Moving Slowly or Fidgety/Restless — More Than Half The Days | 0 |
| Period 5 Day 6/PF-06882961 200mg BID+0.15mg LE & 0.03mg EE/Moving Slowly or Fidgety/Restless — Nearly Every Day | 1 |
| Period 5 Day 6 / PF-06882961 200 mg BID + 0.15 mg LE & 0.03 mg EE / Thoughts You Be Better Off Dead — Not At All | 9 |
| Period 5 Day 6 / PF-06882961 200 mg BID + 0.15 mg LE & 0.03 mg EE / Thoughts You Be Better Off Dead — Several Days | 0 |
| Period 5 Day 6 / PF-06882961 200 mg BID + 0.15 mg LE & 0.03 mg EE / Thoughts You Be Better Off Dead — More Than Half The Days | 0 |
| Period 5 Day 6 / PF-06882961 200 mg BID + 0.15 mg LE & 0.03 mg EE / Thoughts You Be Better Off Dead — Nearly Every Day | 0 |
| Follow Up / Little Interest/Pleasure in Things — Not At All | 11 |
| Follow Up / Little Interest/Pleasure in Things — Several Days | 0 |
| Follow Up / Little Interest/Pleasure in Things — More Than Half The Days | 0 |
| Follow Up / Little Interest/Pleasure in Things — Nearly Every Day | 0 |
| Follow Up / Feeling Down Depressed or Hopeless — Not At All | 11 |
| Follow Up / Feeling Down Depressed or Hopeless — Several Days | 0 |
| Follow Up / Feeling Down Depressed or Hopeless — More Than Half The Days | 0 |
| Follow Up / Feeling Down Depressed or Hopeless — Nearly Every Day | 0 |
| Follow Up / Trouble Falling or Staying Asleep — Not At All | 10 |
| Follow Up / Trouble Falling or Staying Asleep — Several Days | 1 |
| Follow Up / Trouble Falling or Staying Asleep — More Than Half The Days | 0 |
| Follow Up / Trouble Falling or Staying Asleep — Nearly Every Day | 0 |
| Follow Up / Feeling Tired or Little Energy — Not At All | 11 |
| Follow Up / Feeling Tired or Little Energy — Several Days | 0 |
| Follow Up / Feeling Tired or Little Energy — More Than Half The Days | 0 |
| Follow Up / Feeling Tired or Little Energy — Nearly Every Day | 0 |
| Follow Up / Poor Appetite or Overeating — Not At All | 11 |
| Follow Up / Poor Appetite or Overeating — Several Days | 0 |
| Follow Up / Poor Appetite or Overeating — More Than Half The Days | 0 |
| Follow Up / Poor Appetite or Overeating — Nearly Every Day | 0 |
| Follow Up / Feeling Bad About Yourself — Not At All | 11 |
| Follow Up / Feeling Bad About Yourself — Several Days | 0 |
| Follow Up / Feeling Bad About Yourself — More Than Half The Days | 0 |
| Follow Up / Feeling Bad About Yourself — Nearly Every Day | 0 |
| Follow Up / Trouble Concentrating on Things — Not At All | 11 |
| Follow Up / Trouble Concentrating on Things — Several Days | 0 |
| Follow Up / Trouble Concentrating on Things — More Than Half The Days | 0 |
| Follow Up / Trouble Concentrating on Things — Nearly Every Day | 0 |
| Follow Up / Moving Slowly or Fidgety/Restless — Not At All | 11 |
| Follow Up / Moving Slowly or Fidgety/Restless — Several Days | 0 |
| Follow Up / Moving Slowly or Fidgety/Restless — More Than Half The Days | 0 |
| Follow Up / Moving Slowly or Fidgety/Restless — Nearly Every Day | 0 |
| Follow Up / Thoughts You Be Better Off Dead — Not At All | 11 |
| Follow Up / Thoughts You Be Better Off Dead — Several Days | 0 |
| Follow Up / Thoughts You Be Better Off Dead — More Than Half The Days | 0 |
| Follow Up / Thoughts You Be Better Off Dead — Nearly Every Day | 0 |
Collected over From Screening (Days 28 to -2) to follow-up telephone contact (Days 90 to 97) in Part A and from Screening (Days 28 to -2) to follow-up telephone contact (Days 94 to 101) in Part B of the study.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Atorvastatin 20 mg (Part A Period 1) | 0/18 (0%) | 0/18 (0%) | 2/18 (11.1%) |
| Midazolam 5 mg (Part A Period 2) | 0/18 (0%) | 0/18 (0%) | 3/18 (16.7%) |
| PF-06882961 Titration up to 120 mg BID (Part A Period 3) | 0/17 (0%) | 0/17 (0%) | 13/17 (76.5%) |
| PF-06882961 120 mg BID + Atorvastatin 20 mg (Part A Period 4) | 0/13 (0%) | 0/13 (0%) | 5/13 (38.5%) |
| PF-06882961 120 mg BID + Midazolam 5 mg (Part A Period 5) | 0/13 (0%) | 0/13 (0%) | 4/13 (30.8%) |
| PF-06882961 Titration up to 200 mg BID (Part A Period 6) | 0/13 (0%) | 0/13 (0%) | 12/13 (92.3%) |
| PF-06882961 200 mg BID + Atorvastatin 20 mg (Part A Period 7) | 0/5 (0%) | 0/5 (0%) | 5/5 (100%) |
| PF-06882961 200 mg BID + Midazolam 5 mg (Part A Period 8) | 0/6 (0%) | 0/6 (0%) | 2/6 (33.3%) |
| 0.15 mg LE & 0.03 mg EE (Part B Period 1) | 0/17 (0%) | 0/17 (0%) | 5/17 (29.4%) |
| PF-06882961 Titration up to 120 mg BID (Part B Period 2) | 0/16 (0%) | 0/16 (0%) | 15/16 (93.8%) |
| PF-06882961 120 mg BID + 0.15 mg LE & 0.03 mg EE (Part B Period 3) | 0/14 (0%) | 0/14 (0%) | 7/14 (50%) |
| PF-06882961 Titration up to 200 mg BID (Part B Period 4) | 0/12 (0%) | 0/12 (0%) | 12/12 (100%) |
| PF-06882961 200 mg BID + 0.15 mg LE & 0.03 mg EE (Part B Period 5) | 0/9 (0%) | 0/9 (0%) | 7/9 (77.8%) |
| Event | Atorvastatin 20 mg (Part A Period 1) | Midazolam 5 mg (Part A Period 2) | PF-06882961 Titration up to 120 mg BID (Part A Period 3) | PF-06882961 120 mg BID + Atorvastatin 20 mg (Part A Period 4) | PF-06882961 120 mg BID + Midazolam 5 mg (Part A Period 5) | PF-06882961 Titration up to 200 mg BID (Part A Period 6) | PF-06882961 200 mg BID + Atorvastatin 20 mg (Part A Period 7) | PF-06882961 200 mg BID + Midazolam 5 mg (Part A Period 8) | 0.15 mg LE & 0.03 mg EE (Part B Period 1) | PF-06882961 Titration up to 120 mg BID (Part B Period 2) | PF-06882961 120 mg BID + 0.15 mg LE & 0.03 mg EE (Part B Period 3) | PF-06882961 Titration up to 200 mg BID (Part B Period 4) | PF-06882961 200 mg BID + 0.15 mg LE & 0.03 mg EE (Part B Period 5) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NauseaGastrointestinal disorders | 0/18 | 0/18 | 10/17 | 2/13 | 1/13 | 3/13 | 0/5 | 0/6 | 0/17 | 12/16 | 0/14 | 1/12 | 2/9 |
| SARS-CoV-2 test positiveInvestigations | 0/18 | 0/18 | 2/17 | 0/13 | 0/13 | 8/13 | 3/5 | 0/6 | 0/17 | 0/16 | 0/14 | 0/12 | 0/9 |
| HeadacheNervous system disorders | 1/18 | 1/18 | 3/17 | 0/13 | 0/13 | 3/13 | 1/5 | 1/6 | 1/17 | 7/16 | 3/14 | 6/12 | 3/9 |
| Abdominal discomfortGastrointestinal disorders | 0/18 | 0/18 | 5/17 | 0/13 | 1/13 | 2/13 | 0/5 | 0/6 | 0/17 | 7/16 | 1/14 | 4/12 | 3/9 |
| VomitingGastrointestinal disorders | 0/18 | 0/18 | 2/17 | 1/13 | 1/13 | 5/13 | 1/5 | 0/6 | 0/17 | 5/16 | 1/14 | 3/12 | 2/9 |
| ConstipationGastrointestinal disorders | 0/18 | 0/18 | 6/17 | 3/13 | 0/13 | 4/13 | 0/5 | 0/6 | 0/17 | 0/16 | 0/14 | 2/12 | 0/9 |
| Decreased appetiteMetabolism and nutrition disorders | 0/18 | 0/18 | 3/17 | 1/13 | 0/13 | 2/13 | 0/5 | 0/6 | 0/17 | 4/16 | 1/14 | 0/12 | 0/9 |
| DizzinessNervous system disorders | 0/18 | 0/18 | 2/17 | 0/13 | 0/13 | 1/13 | 0/5 | 1/6 | 1/17 | 3/16 | 1/14 | 3/12 | 0/9 |
| DiarrhoeaGastrointestinal disorders | 0/18 | 0/18 | 0/17 | 0/13 | 0/13 | 0/13 | 0/5 | 0/6 | 0/17 | 3/16 | 0/14 | 3/12 | 2/9 |
| FatigueGeneral disorders | 0/18 | 0/18 | 0/17 | 0/13 | 1/13 | 0/13 | 1/5 | 0/6 | 0/17 | 1/16 | 0/14 | 1/12 | 0/9 |
All enrolled participants who received at least 1 dose of study intervention
| Age, Continuous(Years) | All Participants in Part A | All Participants in Part B | Total |
|---|---|---|---|
| Mean (SD) | 41.2 ± 11.63 | 54.5 ± 4.16 | 47.7 ± 11.01 |
| Age, Customized(Participants) | All Participants in Part A | All Participants in Part B | Total |
|---|---|---|---|
| <18 Years | 0 | 0 | 0 |
| 18-25 Years | 2 | 0 | 2 |
| 26-35 Years | 4 | 0 | 4 |
| 36-45 Years | 4 | 0 | 4 |
| >45 Years | 8 | 17 | 25 |
| Sex: Female, Male(Participants) | All Participants in Part A | All Participants in Part B | Total |
|---|---|---|---|
| Female | 2 | 17 | 19 |
| Male | 16 | 0 | 16 |
| Race/Ethnicity, Customized(Participants) | All Participants in Part A | All Participants in Part B | Total |
|---|---|---|---|
| White | 15 | 14 | 29 |
| Black or African American | 2 | 2 | 4 |
| Asian | 1 | 1 | 2 |
| Race/Ethnicity, Customized(Participants) | All Participants in Part A | All Participants in Part B | Total |
|---|---|---|---|
| Hispanic or Latino | 8 | 9 | 17 |
| Not Hispanic or Latino | 10 | 8 | 18 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Ran from Oct 2021 to primary completion in Jul 2022, 8 months.
Results were first posted in Aug 2024, 2 years 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Danuglipron · Atorvastatin